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Summary 
About this report 
This report describes the current prevalence of neural tube defects (NTD) and the trends 
during the past decade. Characteristics and outcomes of the births and demographic and 
pregnancy characteristics of the mothers are presented for the period 1998–2005. Information 
on terminations of pregnancy before 20 weeks gestation is also presented for four 
jurisdictions where such data are available: New South Wales, Victoria, South Australia and 
Western Australia.  
Among other things, this report provides baseline prevalence data for NTD in Australia, 
prior to the implementation of mandatory folic acid fortification of bread flour in September 
2009. It is expected that the information provided will assist in evaluating the effect of 
mandatory folic acid fortification in the future.  
This report was compiled at the request of the Statistical Information Management 
Committee (SIMC) of the Australian Health Ministers Advisory Council, using the data 
collected by the Australian Congenital Anomalies Monitoring System (ACAMS), which is the 
national data collection of congenital anomalies. State and territory birth defect registries and 
perinatal data collections provide data on congenital anomalies to ACAMS.  
What are neural tube defects? 
Neural tube defects are major congenital anomalies that result from very early disruption in 
the development of the brain and spinal cord. There are three distinct forms of neural tube 
defects described in this report: anencephaly, which is the absence of a major part of the brain, 
skull and scalp; encephalocele, which is a protrusion of brain tissue and/or its covering 
membranes through a defect in the skull; and spina bifida, in which the vertebrae that cover 
the spinal cord have one or more openings in the middle, allowing exposure and/or 
protrusion of nervous tissue and coverings with various degrees of damage to nerves.  
How is folic acid connected with NTD? 
Since the 1960s there has been mounting evidence of a decreased prevalence of NTD with 
increased intake of folic acid during the period around conception. Folic acid and folate (the 
anionic form) are forms of Vitamin B.  Folic acid and folate occur naturally in food; folic acid 
may be added to some foods and can also be taken as a supplement. Folate is necessary for 
the production and maintenance of new cells, which is especially important during periods 
of rapid cell division and growth such as infancy and pregnancy.  
Over the past decade Australian governments have actively promoted folic acid intake 
around the time of conception in an attempt to reduce the prevalence of NTD. From 
September 2009 onwards, Australia will join many other developed countries in having 
mandatory folic acid fortification of flour for bread making, in an attempt to further reduce 
the prevalence of NTD.  
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How many NTD are there in Australia? 
This report presents the prevalence and trends of births with NTD for all jurisdictions in 
Australia, except Northern Territory, from 1998–2005. Main findings include: 
• There were a total of 944 births over this period affected by NTD. Of these births, 523 
were live births and 421 were fetal deaths (still births and terminations after 20 weeks 
gestation). This equates to a prevalence of neural tube defects (NTD) among births of  
4.6 per 10,000. 
• There was no significant decrease in NTD among births during the period 1998–2005, 
despite early diagnosis, health education and health promotion programs and 
voluntary fortification of food with folic acid.  
• While there has been little change in the prevalence of NTD amongst births, there has 
been a decrease in the overall prevalence of NTD (taking into account births as 
described above as well as pregnancies that may have been terminated before 20 
weeks gestations due to early detection of an NTD). Results from the four states that 
include these data indicate that during 1998–2005 there were a total of 1,657 
pregnancies affected by NTD.  However, the prevalence based on four states is likely 
to be an underestimate. Of these pregnancies, 903 were terminated prior to 20 weeks 
gestation. The overall prevalence of NTD in these four states, including early 
terminations, was more than twofold higher (10.1 per 10,000 pregnancies in 2005) 
than the prevalence at birth. This represents a 32.7% decrease over the 14 years 
between 1992 and 2005.  
• Data from the four states for the period 1998–2005 reveal that more than 77% of 
pregnancies affected with NTD were fetal deaths or were managed by pregnancy 
terminations.  
 
 Other findings include: 
• Younger women are more likely to have NTD-affected pregnancies than older 
women: teenage women had the highest rate and women aged 30–34 years the 
lowest. 
• The rate of pregnancies affected with NTD was higher for women living in remote 
areas than for women living in major cities. 
• Multiple pregnancies were more likely to have NTD than singleton pregnancies.  
• Indigenous women had a higher rate of NTD-affected pregnancies than non-
Indigenous women. 
• The prevalence of NTD in Australia was similar to or slightly higher than other 
developed countries. 
What is needed for future reporting? 
As at least 50% of the pregnancies with NTD were terminated before 20 weeks gestation, 
collection of data on early terminations is critical in reporting the accurate prevalence of 
NTD.  
A program of national data development is underway with the aim of developing a national 
minimum data set (NMDS) for congenital anomalies, with the expectation of providing high 
quality national data on congenital anomalies.  
This will be vital for evaluating the effectiveness and outcomes of mandatory folic acid 
fortification of bread making flour. 
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Introduction 
Neural tube defects (NTD) are common major congenital anomalies that result from very early 
disruption in the development of the brain and spinal cord. Details of three distinct forms of 
neural tube defects are described in this report: anencephaly which is the absence of a major 
part of the brain, skull and scalp; encephalocele which is a protrusion of brain tissue and/or its 
covering membranes through a defect in the skull; and spina bifida in which the vertebrae that 
cover the spinal cord have one or more openings in the middle, allowing exposure and/or 
protrusion of nervous tissue and coverings with various degrees of damage to nerves. Each of 
these is described in more detail in later sections of the report. 
NTD are a significant public health concern in Australia. With advanced medical technology, 
most NTD are diagnosed early in pregnancy. Many affected women opt for termination of 
pregnancy while some women may have stillbirths. However termination of pregnancy is not 
acceptable for some women for cultural, religious or personal reasons. The survivors are 
known to face frequent morbidity and are at high risk of mortality. Those families who are 
affected experience considerable emotional and economic difficulties. Hence, primary 
prevention of neural tube defects is an important health issue. 
The mechanisms which cause NTD are still not fully understood, but evidence has shown that 
increased intake of folic acid during the periconceptional period can decrease the prevalence 
of NTD. Therefore, many government and non-government organisations have conducted 
health education and health promotion programs to encourage women contemplating 
pregnancy to increase their intake of folic acid.  Food Standards Australia New Zealand 
(FSANZ) has allowed voluntary fortification of food with folic acid in Australia since 1995. 
These initiatives have not decreased the prevalence of NTD to the extent expected, so in June 
2007 the Commonwealth Government in partnership with state and territory governments 
agreed to implement mandatory folic acid fortification of bread flour within a two-year 
timeframe.  
The objective of this report is to provide a baseline prevalence of neural tube defects in 
Australia, prior to the implementation of mandatory folic acid fortification of bread flour. It is 
expected that the information provided in this report will assist in evaluating the effect of 
mandatory folic acid fortification in the future. This report illustrates the current prevalence of 
NTD and the trends during the past decade. Characteristics and outcomes of the births and 
demographic and pregnancy characteristics of the mothers are presented for the period, 1998 
to 2005. Information on terminations of pregnancy before 20 weeks gestation is also presented 
for four jurisdictions that include New South Wales, Victoria, South Australia and Western 
Australia. The Northern Territory data were not available for this report.  
This report was compiled at the request of the Statistical Information Management Committee 
(SIMC) of the Australian Institute of Health and Welfare, using the data collected by the 
Australian Congenital Anomalies Monitoring System (ACAMS), which is the national data 
collection of congenital anomalies. State and territory birth defect registries and perinatal data 
collections provide data on congenital anomalies to the ACAMS. This report is part of the 
project funded by the Australian Health Ministers’ Advisory Council for the development of a 
national minimum data set for congenital anomalies with the expectation of collecting high 
quality, consistent congenital anomalies data nationally.  
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Background 
Development and outcomes of neural tube defects 
The neural tube, which develops into the human brain and spinal cord, derives from the 
embryonic dorsal ectoderm that resembles a plate in the early embryo. During the third week 
of embryonic life the lateral edges of this plate thicken and grow towards each other and fuse 
along the midline to form a tube by the end of the fourth week. If the neural tube fails to close 
it affects the development of surrounding tissues resulting in defects of the bones, muscles 
and skin that cover the neural structures. In open NTD, the nervous tissues are exposed to the 
amniotic fluid which has a corrosive effect on nervous tissues and further damages the 
surrounding nerves (Ellenbogen 2006).  
The outcome for individuals with NTD depends on the site, the extent of the defect, the type 
of nerve cells that are involved and the extent of secondary abnormalities. Although most 
NTD are considered to result from a primary failure of the embryonic neural tube to close, 
there is some evidence supporting the possibility of a closed neural tube secondarily 
reopening, resulting in NTD (Campbell & Sohal 1990, Padmanabhan 2006). 
The NTD can be open or closed (Lemire 1988). The mildest type of closed NTD is spina bifida 
occulta which is a benign bony change in one or more vertebrae, but not involving the nerves 
within the spinal column. This could be more common than the other NTD but prevalence is 
not known because it may not be obvious and may not show any symptoms. This condition is 
not counted as an NTD in this report. Open NTD can range from a single small opening in the 
vertebral canal, to complete lack of closure of the neural tube, which will result in the most 
severe forms of these defects.  
Anencephaly is the most severe form of NTD that results from failure of the closure of the 
head end of the neural tube and is not compatible with life. A fetus with anencephaly may 
result in a miscarriage or can be born with a rudimentary brainstem where the baby may die 
at or within a few days of birth. 
Spina bifida results from failure of the closure of the lower end of the neural tube. Babies who 
survive, usually as a result of extensive medical and surgical care may have mild to severe 
symptoms depending on the site and extent of nerve exposure or damage (Botto et al. 1999). 
Surviving infants with spina bifida are likely to have severe life-long disabilities (Date et al. 
1999). About 10–15% of cases have spina bifida occulta. The position, extent and types of 
nerves involved will determine the abnormalities associated with spina bifida. Lower limb 
paralysis, incontinence, hydrocephalus and learning difficulties can all be present.  
An encephalocele results from failure of the surface ectoderm to separate from the 
neuroectoderm that leads to a bony defect in the skull, allowing herniation of the meninges or 
of the brain tissue. Some of them survive depending on the severity of the condition. 
Survivors of spina bifida and encephalocele may need neonatal intensive care management, 
surgery, rehabilitation and other specialised management for long periods which require 
substantial resources. In 2003, the National Center for Birth Defects and Developmental 
Disabilities (Centers for Disease Control and Prevention, USA) showed that each case of spina 
bifida prevented saves an estimated US$500,000 in lifetime costs. The consequences of NTD 
extend beyond the affected individual to the family for whom there are the emotional and 
financial costs of caring for a child with disabilities.  Society as a whole will carry much of the 
burden of providing health and social care to affected individuals.   
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Diagnosis of neural tube defects 
The prevalence of NTD at birth depends on the availability of prenatal screening, quality of 
available methods, and the use of prenatal screening as well as the acceptance of termination 
of pregnancy as a way of managing affected pregnancies. The option of termination may be 
unacceptable for some cultures and individuals. This contributes to variations in prevalence at 
birth and the cost to health care services for surviving children and adults with neural tube 
defects. 
With the availability of technology, most affected pregnancies are diagnosed early and many 
are managed by termination of pregnancy. The methods used for diagnosis are: 
• maternal serum alpha fetoprotein, a screening test that is performed on the blood of 
pregnant women, at approximately 16–18 weeks of pregnancy 
• high-resolution ultrasound 
• amniocentesis, a test that samples the amniotic fluid after 15 weeks of pregnancy. 
Each of these tests has various risks and benefits. Therefore, a genetic counsellor or other 
health care provider should be consulted to explain in detail each procedure, their risks and 
benefits, and other available options. Using these methods, 85–90% of affected pregnancies 
can be diagnosed. A study in South Australia showed a significant increase in the rate of 
antenatal detection of NTD through the state-based screening program (ultrasound and/or 
maternal serum alpha fetoprotein), from 76.3% in 1986 to 95.2% in 2004 (Muller et al. 2007). 
Aetiology 
The exact aetiology of NTD is poorly understood and is suggested to be multifactorial in 
origin. Epidemiological studies have established clear variations in the occurrence of NTD 
among different ethnic groups, different socioeconomic levels and different geographical 
distributions, and have shown recurrences in families. The NTD are expected to have a 
significant genetic component in the aetiology that interacts with nutritional factors and a 
number of environmental factors (Padmanabhan 2006). NTD are not only disorders of 
embryologic induction but also disorders of cellular migration and include the secondary 
mechanical complications that occur with an unprotected nervous system (Kashani 2001). 
Specifically, the amniotic fluid can have a caustic and destructive effect on the open neural 
structures (Ellenbogen 2006). 
The prevalence of NTD among first and second-degree relatives of affected infants appears to 
be significantly higher than that reported for the general population. Females and 
monozygotic twins appear to be particularly prone to NTD (Padmanabhan 2006). Family 
studies suggest the recurrence risk for first-degree relatives of affected individuals could be 
approximately 1 in 30. For second-degree relatives (the children of the mother's sisters and 
brothers) the risk is approximately 1 in 220 (Shurtleff 2004). Despite the declining prevalence 
of NTD in many parts of the world, NTD recurrence within affected families has not declined 
(Czeizel & Metneki 1984). 
Anencephaly is reported to be particularly more prevalent in certain communities with a high 
rate of consanguinity (Zlotogora 1997; Al-Gazali et al. 1999). Spontaneous abortions with NTD 
have a significant association with chromosomal aberrations, suggesting a genetic component 
to their aetiology (Coerdt et al. 1997; McFadden & Friedman 1997). NTD are a feature of 
known genetic syndromes, such as trisomy 13, trisomy 18, certain chromosome 
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rearrangements and Meckel-Gruber syndrome. Spina bifida occurs more frequently in babies 
with autosomal trisomies.  
In humans, carbamazepine and valproic acid have been definitively identified as teratogens. 
Valproic acid is a known folate antagonist and its association with NTD may be through that 
action. A woman taking valproic acid during pregnancy has an estimated risk of 1–2% of 
NTD-affected pregnancy (Lindhout et al. 1992; Duncan et al. 2001). A meta-analysis has 
shown that maternal hyperthermia during early pregnancy is associated with increased 
incidence of NTD (odds ratio 1.95), showing that the neural tube is heat sensitive in human 
embryos (Moretti et al. 2005). 
Prevention of neural tube defects  
Since the 1960s, observational studies, case control studies and randomised control trials have 
provided evidence of a decreased prevalence of NTD with increased intake of folic acid 
during the periconceptional period. After the publication of the results of randomised 
controlled trials, for example the Medical Research Council Vitamin Study in 1991 which 
reported a 72% reduction in the recurrence of NTD and the Hungarian study by Czeizel et al. 
(1992) that showed a 100% reduction in NTD in women who had periconceptional folic acid, 
some countries initiated the active promotion of the use of periconceptional folic acid for 
women planning to become pregnant.  
The Commonwealth and state and territory governments of Australia have also actively taken 
steps to promote periconceptional folic acid intake. Experts interested in NTD have made 
enormous efforts to educate susceptible women, health professionals and the people at risk on 
the advantages of increased intake of folic acid during the period immediately before 
pregnancy and in the early weeks of pregnancy. There have been many extensive health 
promotion programs with the aim of increasing the recognition of the importance of 
periconceptional folate. 
In 1994, the National Health and Medical Research Council (NHMRC) of Australia 
recommended that women who are at low risk and are planning to become pregnant should 
take 0.5 mg of folic acid daily and women who are at high risk should take 5 mg of folic acid 
daily around the periconceptional period. The NHMRC also recommended that food should 
be fortified with folic acid. However, adherence to the recommendations of the NHMRC 
would be expected to decrease but not eliminate the prevalence of neural tube defects.  
Food Standards Australia and New Zealand has allowed voluntary fortification of food with 
folic acid since 1996. Since then many food items have been fortified with folic acid 
throughout Australia. Following all these initiatives, there was a reduction of NTD in 
Australia (Chan et al. 2001, Halliday & Riley 2000, and Bower et al. 2002). However, this 
reduction was not seen among all ethnic groups and all socioeconomic groups. In Western 
Australia, there has been a 30% fall in NTD among the non-Indigenous population, but no 
change has been seen in the Indigenous population (Bower et al. 2004C). A series of surveys in 
Western Australia between mid-1992 and March 1995 in relation to training and health 
promotion activities showed that women who had education up to year 12 or less were not as 
well informed as women with a tertiary education. Those study participants were asked if 
they would take folic acid if they plan to become pregnant. Only about two-thirds of those 
women stated that they would take supplementary folate if they plan to become pregnant. 
The main barrier to take folate supplements as noted in this study was an unwillingness to 
take tablets and a preference for a dietary increase of folate (Bower et al. 1997). 
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A survey in South Australia found that only 30% of women achieved full compliance of 
recommended folate levels. This survey showed that some supplements on the market had 
lower levels of folic acid than the recommended level for pregnancy. Only 18% of the survey 
participants knew the daily recommended dosage of folic acid during pregnancy. Generally 
consumers rely on the manufacturer to include an adequate amount of folic acid and do not 
expect low vitamin levels in supplements (Conlin et al. 2006). Under these circumstances, 
women who consumed supplements expect that they have had enough folic acid to prevent 
NTD, but in reality they may not have consumed the adequate amounts. 
In 2006, Watson et al. reported that the folic acid supplement intake among women prior to 
conception and in the first three months of pregnancy in Victoria was 36% and in New South 
Wales was 46%. In 2006, the Queensland Healthy Food Access Basket Survey found that prices 
for fruit, vegetables and legumes which are major sources of dietary folate, were commonly 
21–30% higher in remote areas of Queensland compared with prices in major cities. Therefore 
consumption of these foods rich in folic acid by the target population in remote areas could be 
lower than in cities.  
In the United States, a March of Dimes survey in 2005 found that many women of 
reproductive age were unaware of the importance of having folic acid in the period prior to 
the pregnancy and there is poor compliance among women who opt to take folic acid 
supplements. Significant levels of public health resources are required to support the 
implementation and ongoing promotion of dietary education and supplement use. 
Maintenance of the knowledge gained by health promotion campaigns is difficult, especially 
because the target population is constantly changing. The provision of health promotional and 
educational materials only in English language also makes it difficult for non-English 
speaking women to absorb the message about folic acid. It has been shown that people with 
higher socioeconomic and educational levels benefit most from dietary education and 
promotion of supplement use, making these strategies inequitable (Bower et al. 2005). 
The Interim evaluation of the voluntary folate fortification policy by Abraham and Webb (2001) 
showed that the criterion for effectiveness defined by the NHMRC Expert Panel, i.e. at least 
70% of women consuming more than 400 μg of folate per day, has not been met under 
voluntary fortification. By November 1998, voluntary fortification had resulted in only a small 
increase in mean folate intake (11%) among the target population. 
As many pregnancies could be unplanned and terminations of pregnancy are not acceptable 
for some women, intake of folic acid throughout the reproductive age will assist in achieving 
maximum prevention of NTD. Under these circumstances, fortification of staple food with 
folic acid is an effective method of increasing folic acid intake in the target group during the 
periconceptional period.  
In 2005, the National Institute of Clinical Studies has also identified mandatory folate 
fortification of flour as a key issue.  
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Mandatory folic acid fortification in Australia 
The move to implement mandatory folic acid fortification in Australia has been driven by 
overwhelming evidence from Australian and international research studies. In May 2004, the 
Australia and New Zealand Food Regulation Ministerial Council requested Food Standards 
Australia New Zealand (FSANZ) to investigate mandatory fortification of food with folic acid 
with the expectation of reducing the incidence of NTD. FSANZ established the Folate 
Scientific Advisory Group (FSAG) to provide scientific advice in relation to ‘Proposal P295 
Consideration of mandatory fortification with folic acid’. Members of the FSAG are primarily 
academia from Australia and New Zealand and collectively have researched and published 
widely on the benefits and risks of folic acid in public health and clinical medicine. 
In developing the mandatory folic acid fortification standard, FSANZ comprehensively 
assessed the potential health benefits and risks from increasing folic acid intake within the 
population. The overall effects of mandatory fortification on consumers, industry and 
government enforcement agencies were also assessed.  
These safety assessments demonstrated that the increased intake at the expected level of 
fortification is harmless for the general population. FSANZ selected bread-making flour as the 
food vehicle for mandatory folic acid fortification in Australia. 
The Australian and New Zealand Food Regulation Ministerial Council approved the 
mandatory fortification of wheat flour with folic acid in Australia, at the recommendation of 
the FSANZ in June 2007. The draft standard requires the mandatory addition of folic acid to 
wheat flour for bread making within the prescribed range of 200–300 µg per 100 grams of 
flour. This level of fortification is expected to prevent between 14 and 49 neural tube defects 
per year, when combined with existing voluntary fortification permissions and current levels 
of supplemental use. The standards allow the food industry two years to prepare for folic acid 
fortification which will become legally enforceable in September 2009. In adopting the new 
standard, the Ministerial Council has exempted organic wheat flour used for bread making 
from fortification.  
An extensive monitoring system is being finalised to determine the effects of mandatory folic 
acid fortification. A comprehensive independent review of the mandatory fortification will be 
initiated two years after implementation of the standard. The review will consider health 
effects and the general effectiveness of the initiative.  
However, FSANZ identified a need to establish a national monitoring and surveillance 
system, prior to the implementation of mandatory fortification which will assist in assessing 
the impact of mandatory fortification. FSANZ stated that the responsibility for establishing 
and funding a monitoring system would require the concomitant involvement of health and 
regulatory agencies at the Commonwealth and the state and territory levels.  
At its June 2005 meeting, the Australian Health Ministers Advisory Council (AHMAC) agreed 
to recommend to Health Ministers that any decision on mandatory fortification should be 
accompanied by a national monitoring system for NTD. As a result, the AHMAC funded the 
development of a national minimum data set for congenital anomalies and this report on 
NTD. 
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Prevalence of neural tube defects in other countries 
A decreasing trend of NTD has been noted in many developed countries during the last three 
decades (Olney 2002). The introduction of prenatal screening for NTD, an understanding of 
the relationship between folic acid intake and NTD, establishment of prevention programs 
and the fortification of food with folic acid could have contributed to this decreasing trend.  
In the United Kingdom and Ireland, yearly prevalence of NTD declined from 45 per 10,000 
births in 1980 to 10–15 per 10,000 in the 1990s. This decline was noted before any 
periconceptional folic acid supplementation policy initiatives. The prevalence in the United 
Kingdom and Ireland fell by 32% continuing a stronger pre-existing trend and remains slightly 
higher than overall European levels (Botto et al. 2005). 
In the United States, prior to 1998, spina bifida and anencephaly together affected 
approximately 4,000 pregnancies resulting in 2,500 to 3,000 US births annually. In 1992, the US 
Public Health Service issued a recommendation that all US reproductive-age women who are 
capable of becoming pregnant should consume 400 µg of folic acid daily. In 1998, a survey 
indicated that only 29% of US women were following this recommendation. The US Food and 
Drug Administration authorised the addition of folic acid to enriched grain products in March 
1996 and made compliance mandatory by January 1998. The level of fortification was expected 
to add approximately 100 µg of folic acid to the daily diet of the average person and to result 
in approximately 50% of all reproductive-age women receiving 400 µg of folate from all 
sources. Following this initiative, a 19% reduction in NTD was reported in the USA in 1999 
compared with 1996. The spina bifida prevalence declined by 23% (Honein 2001). 
After implementation of mandatory folic acid fortification, Canada reported a 46% reduction 
in NTD (De Wals et al. 2007). More than 40 other countries have implemented mandatory folic 
acid fortification subsequent to the US and Canada (Maberly & Stanley 2005). 
In Northern China there was a 79% reduction observed in NTD after the addition of folic acid 
supplements to women’s diets (Berry et al. 1999). 
 
Benefits and risks of folic acid fortification 
Increased folate consumption has been shown to decrease the prevalence of neural tube 
defects by about 40–70%. Mandatory fortification of bread flour with folic acid will allow all 
women who become pregnant to have increased blood folate levels and eliminate the need to 
take supplements. Women who are not aware of the importance of folic acid, who cannot 
afford it, who do not like or forget to take pills and women who have unplanned pregnancies, 
will all benefit from increased blood folate levels resulting from folic acid fortification.  
There is a concern that folic acid fortification may mask vitamin B12 deficiency, mainly in the 
elderly. However, severe vitamin B12 deficiency is uncommon and folic acid does not prevent 
the neurologic consequences of vitamin B12 deficiency (Malouf et al. 2003). It was suggested 
that people with deficiency will present with early neurological symptoms and available 
serological tests can easily detect this condition. Nevertheless, the anticipated fortification 
level is not expected to mask anaemia. A study in NSW (Flood 2001) has shown that it is 
unlikely to have a large increase in number of older people consuming folic acid more than 
the upper safety level. 
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Elevated total homocysteine levels have shown to cause increased risk of arteriosclerotic 
vascular diseases (Boushey et al. 1995). Some studies have shown lowered homocysteine 
levels after fortification of food with folic acid (Boushey et al. 1995; Jacques et al. 1999). A 
study conducted in Western Australia from 1995 to 2001 also has shown a decrease in total 
homocysteine levels in blood, after voluntary fortification of food with folic acid (Hickling et 
al. 2005). Therefore, it is anticipated that increased blood folate may lower the rates of heart 
disease and stroke. Malinow et al. (1998) have suggested that folic acid fortification at levels 
higher than that recommended for fortification is required to reduce total homocysteine levels. 
Hence further studies are required to determine whether folic acid fortification may prevent 
vascular disease.  
There may be similar protective effects of folic acid on other congenital anomalies such as oral 
clefts, limb reduction defects and congenital heart defects. Findings of studies so far have not 
confirmed whether there are any protective effects.   
Some studies suggested that folate can increase twinning rates independently of the use of 
assisted reproductive technology (Signore et al 2005, Waller et al 2003). However, findings 
from a large, population-based cohort study in China found that consumption of folic acid 
supplements during pregnancy was not associated with an increased occurrence of multiple 
births (Li et al. 2001). A systematic review of the recent literature suggests that well designed, 
long-term follow-up studies be carried out in places where fortification with folic acid has 
been introduced, focusing on dose response and obtaining accurate data on infertility 
treatment (Muggli & Halliday 2007). 
Folate is a key component of DNA synthesis and repair, and it is biologically plausible that 
folate can both protect against the initiation of, and enhance the progression of, cancer (Duthie 
1999; Kim 2004). Folate deficiency has an inhibitory effect whereas folate supplementation has 
a promoting effect on the progression of established neoplasms. In contrast, folate deficiency 
in normal epithelial tissues appears to predispose them to neoplastic transformation, and 
modest levels of folate supplements suppress the development of tumours in normal tissues 
(Kim 2003). Some studies could not show an increased or decreased risk of breast or colorectal 
cancer with increased use of folic acid (Stolzenburg-Solomon et al. 2006; Tjonneland et al. 
2006; Charles et al. 2004; Fuchs et al. 2002). A meta-analyses of observational and genetic 
association studies of folate intake and breast cancer risk concluded that there was no 
evidence of increased folate intake protecting against breast cancer (Lewis et al. 2006). 
Some studies have shown that folic acid supplementation has been associated with a 15% 
increase in spontaneous abortions (Cziezel 1992; MRC 1991). However, in a large study 
conducted in China, Gindler et al. (2001) found no evidence that the daily consumption of 
400 μg of folic acid during the periconceptional period influenced the risk for spontaneous 
abortion.  
Anticonvulsants reduce serum folate levels, and treatment with folic acid can result in 
reductions in circulating levels of the anticonvulsant. This can subsequently lead to an 
increased numbers of seizures in patients who take anticonvulsants. 
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Methods 
Data sources 
The Australian Congenital Anomalies Monitoring System (ACAMS) collates data submitted 
from state and territory birth defect and perinatal data collections in each of the jurisdictions 
with the exception of the Northern Territory.  Since 1998 the data have been obtained in a 
standardised format. The ACAMS currently includes congenital anomaly information for 
births occurring in the years up to 2003. Additional data for births with NTD in 2004 and 2005 
were requested from the states and territories specifically for this report. The ACAMS data 
have been checked for completeness and validity. Records with missing or improbable data 
values were queried with the relevant providers, who were in most cases, able to correct and 
resubmit the records. 
Queensland, Tasmania and the Australian Capital Territory rely solely on information 
reported in their perinatal data collections for information about congenital anomalies and 
only abnormalities diagnosed prior to discharge from hospital can be included. New South 
Wales, Victoria, Western Australia and South Australia have Birth Defect Registers with 
multiple sources of ascertainment. In these states the data about congenital anomalies are 
supplemented by information from other hospitals, cytogenetic laboratories, perinatal death 
certificates, general practitioners or other doctors, autopsy reports and notifications of 
terminations of pregnancy. The notification period varies: Victoria collects data on children up 
to 15 years of age; Western Australia up to 6 years of age; South Australia up to 5 years of age; 
and New South Wales up to 1 year of age.   
South Australia has legislation for mandatory reporting of congenital anomalies data 
irrespective of gestational age. Therefore, data from the South Australian Birth Defect Register 
provide almost complete data on congenital anomalies. Western Australia has statutory 
notification of termination of pregnancy since 1998 and data is expected to be near complete. 
A study on the completeness of data has shown that the Western Australian Birth Defects 
Register has been collecting near complete data since prior to 1998 (Bower et al. 2001). The 
Victorian Birth Defect Register also actively collects data and a study has shown that the data 
on NTD are almost complete (Riley et al. 2004). The Birth Defect Register in New South Wales 
relies on voluntary reporting of information about congenital anomalies. Hence in New South 
Wales the reporting of NTD is not considered to be complete. In particular, there may be data 
missing on terminations of pregnancy carried out in the private sector.  
Differences in ascertainment of congenital anomalies in the states and territories are not likely 
to substantially affect estimates of the prevalence of NTD at birth. NTD, with a few exceptions, 
are obvious at birth. Those that are diagnosed later or missed will be those with very minor 
degrees of spina bifida or the rare cases of spina bifida occulta. Spina bifida occulta is not 
considered as an NTD for this report.  
In all jurisdictions, perinatal data collections gather information about live births and 
stillbirths (fetal deaths of at least 20 weeks of gestation or at least 400g birthweight). Stillbirths 
in all states and territories include termination of pregnancy carried out at 20 weeks gestation 
or thereafter or resulting in the delivery of a fetus weighing 400g or more.  Some states are 
able to distinguish these late terminations of pregnancy from still births, but some states 
cannot differentiate them. Therefore terminations of pregnancy with at least 20 weeks 
gestation and stillbirths are included as births and identified as fetal deaths in this report. 
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Information about NTD in the period 1992–1997 is available for four states. For this period, the 
Victorian data were obtained from data available in the National Congenital Malformations 
and Birth Defects Data Collection which preceded ACAMS. Western Australia and South 
Australia resubmitted data for these years. Information for New South Wales was obtained 
from published reports; New South Wales mothers and babies 1998 (DOH 2000) and New 
South Wales mothers and babies 2000 (DOH 2001).  
Denominators to compute rates are based on the state or territory of occurrence of births and 
were obtained from the National Perinatal Data Collection. 
 
Definitions  
Anencephaly  
A congenital anomaly characterised by the total or partial absence of the cranial vault, the 
covering skin, and the brain. The brain could be reduced to a small mass. Anencephaly 
includes infants with craniorachischisis, iniencephaly and other neural tube defects such as 
encephalocele or open spina bifida, when associated with anencephaly. This excludes 
acephaly, that is, absence of the head observed in amorphous acardiac twins. 
The following codes were used to classify this condition: 
ICD-9-BPA codes: 740.00–740.29 or ICD-10-AM codes: Q00.0–Q00.2 
 
Spina bifida  
A family of congenital anomalies due to failure in the closure of the spinal column 
characterised by herniation or exposure of the spinal cord and/or meninges through an 
incompletely closed spine. Spina bifida in this report includes meningocele, 
meningomyelocele, myelocele, myelomeningocele and rachischisis. Spina bifida is not counted 
when present with anencephaly. This excludes spina bifida occulta and sacrococcygeal 
teratoma without dysraphism. 
The following codes were used to classify these conditions: 
ICD-9-BPA codes: 741.00–741.99 or ICD-10-AM codes: Q05.0–Q 05.9 
 
Encephalocele  
A congenital anomaly characterised by herniation of the brain and/or meninges through a 
defect in the skull. Encephalocele is not counted when present with spina bifida or 
anencephaly. 
The following codes were used to classify this condition: 
ICD-9-BPA codes: 742.00–742.09 or ICD-10-AM codes: Q01.0- Q01.2, Q01.8, Q01.9 
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Data elements  
Sex 
Data on the sex of each baby were reported as male, female, indeterminate or not stated.  
Gestational age 
The estimated gestational age of the baby is given in completed weeks. This may be calculated 
from the first day of the last menstrual period, ultrasound findings and/or be determined by 
clinical assessment. 
Birthweight 
Birthweight is the first weight of the liveborn or stillborn baby obtained after birth, or the 
weight of the neonate or infant on the date admitted if this is different from the date of birth. 
Maternal age 
Mother’s age was calculated by subtracting their date of birth from the date of birth of their 
baby. Some states provided maternal age, not the maternal date of birth. Maternal age is 
presented by five-year age groups.  
Indigenous status 
Only the Indigenous status of the mother was reported to the ACAMS. In this report, the 
Indigenous women include mothers who were in the categories of Aboriginal but not Torres 
Strait Islander origin, Torres Strait Islander but not Aboriginal origin, or Aboriginal and 
Torres Strait Islander origin. The category reported as non-Indigenous was of neither 
Aboriginal nor Torres Strait Islander origin.  
Remoteness of area of usual residence 
The postcode was provided by states and territories for all records. The remoteness of area of 
usual residence was assigned using postcodes provided to the NPSU. This classification is 
based on the Australian Standard Geographical Classification (ASGC) remoteness structure 
(ABS 2001). Because of the small numbers in the data presented, the Remoteness Areas of 
usual residence categories in this report are presented under three headings: Major Cities, 
Regional and Remote. (Inner regional and Outer regional are reported as Regional; Remote 
and Very remote are reported as Remote.) 
Plurality 
Plurality refers to the number of babies resulting from a single pregnancy. In this report, the 
plurality category is ‘singleton’ for single births, and multiple for twins, triplets, quadruplets, 
quintuplets and other.  
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Analysis 
Two prevalence rates have been calculated: the prevalence rate of NTD amongst births; and 
the prevalence rate of NTD amongst births and terminations of pregnancy (TOP).  The 
prevalence rate of NTD in births is calculated as the proportion of total births with NTD.  
 
Prevalence of NTD at birth = number of births with NTD/number of total births 
 
The data from South Australia, Western Australia, Victoria and New South Wales include 
data on births as well as terminations of pregnancy at all gestational ages. Therefore, these 
data were used to provide an estimated prevalence for the whole country. However, 
considering the incompleteness of the data from New South Wales, another estimate was also 
provided using data from three states: Victoria, South Australia and Western Australia  
 
The estimated prevalence rate of NTD amongst births and TOP is calculated as a ratio of the 
number of NTD and the number of total births.   
 
Prevalence of NTD in pregnancies = number of pregnancies with NTD/ number of total births 
 
Total births include live births and stillbirths. The number of total births in the relevant years 
and jurisdictions used as denominators were obtained from the National Perinatal Data 
Collection. All rates at birth and estimated rates that include terminations of pregnancy are 
expressed per 10,000 births (live births and fetal deaths of at least 20 weeks gestation or at 
least 400 grams birthweight). 
Statistically significant differences in maternal characteristics were determined by comparing 
prevalence ratios and the confidence intervals around those ratios.  The confidence intervals 
around prevalence ratios were calculated using a method described by Armittage and Berry, 
(1994). 
Prevalence ratio (PR) = prevalence in exposed/prevalence in unexposed 
 
For data analysis, SPSS 15.1 software was used. 
There may be slight variations between data given in this report and state and territory 
reports because of updates to data in state and territory databases.  
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Neural tube defects among births 
Neural tube defects include: anencephaly, spina bifida and encephalocele. 
ICD-9-BPA codes: 740.00–742.09   
ICD-10-AM codes: Q00.0–Q00.2, Q05.0–Q05.9, Q01.0–Q01.2, Q01.8, Q01.9 
Prevalence among births 
In Australia, the average prevalence of NTD among births was 4.6 per 10,000 births for the 
period 1998–2005. Births in this report include all births and fetal deaths at 20 weeks gestation 
or later or with a birthweight of at least 400 grams. Fetal deaths include stillbirths and 
pregnancy terminations of at least 20 weeks gestation. 
With the availability of improved technology for early diagnosis and facilities for termination 
of pregnancy, a decline in NTD has been seen among births in many developed countries. 
However, in Australia, despite all available facilities, health education and health promotion 
programs through government and non-government organisations and voluntary fortification 
of food with folic acid, there seems to be no decrease in NTD among births during the period 
1998 to 2005. The prevalence decreased by about 18% from 5.0 per 10,000 births in 1998 to 4.1 
per 10,000 births in 2003, but it had returned to 5.0 per 10,000 births in 2004 (Figure 1). 
More than half of those births were live births, and the prevalence of live births with NTD was 
2.6 per 10,000 births. The fetal death rate was about 2.0 per 10,000 births; this rate has not 
changed significantly since 1998 (Table 1.1). Of the liveborn babies, about 71% were alive on 
day 28 (1.8 per 10,000 live births). In 2005, the proportion of babies with NTD who were alive 
on day 28 had increased to about 76% and the proportion of neonatal deaths had decreased 
(Table 1.2). With advancing medical knowledge and technology, more babies may survive and 
live longer, requiring long-term medical care and rehabilitation.  
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Year 
Rate/10,000 births 
            
Figure 1: Rate and confidence intervals of neural tube defects among births, Australia, 1998–2005 
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Table 1.1: Number and rates of NTD among births(a) as reported to the ACAMS, Australia, 1998–2005 
 Live births  *Fetal deaths  All births 
Year  Number Per cent(b) Rate(c)   Number Per cent(b) Rate(c)   Number Rate(c) 
1998 73 57.9 2.9 53 42.1 2.1 126 5.0 
1999 72 61.5 2.8 45 38.5 1.8 117 4.6 
2000 74 62.2 2.9 45 37.8 1.8 119 4.7 
2001 58 52.3 2.3 53 47.7 2.1 111 4.4 
2002 57 51.8 2.3 53 48.2 2.1 110 4.4 
2003 48 46.6 1.9 55 53.4 2.1 103 4.1 
2004 71 55.9 2.8 56 44.1 2.1 127 5.0 
2005 70 53.4 2.6 61 46.6 2.2 131 4.9 
1998–2005 523 55.2 2.6  421  44.8 2.0  944 4.6 
(a) Includes all live births, stillbirths and pregnancy terminations of at least 20 weeks gestation or at least 400 g birthweight.  
(b) Percentage of all births with NTD. 
(c) Rates are per 10,000 live births and stillbirths. 
*       Still births and pregnancy terminations of at least 20 weeks gestation are included in fetal deaths. 
 
 
 
Table 1.2: Outcomes of live births with NTD, Australia, 1998–2005 
  Live births  Alive on day 28  Neonatal deaths 
 Year Number Number Per cent(a) Rate(b) Number Per cent(a) Rate(b) 
Outcome 
not 
stated 
1998 73 49 67.1 2.0 24 32.9 1.0 0 
1999 72 53 73.6 2.1 19 26.4 0.8 0 
2000 74 56 75.7 2.2 18 24.3 0.7 0 
2001 58 42 72.4 1.7 15 25.9 0.6 1 
2002 57 39 68.4 1.6 18 31.6 0.7 0 
2003 48 32 66.7 1.3 16 33.3 0.6 0 
2004 71 48 67.6 1.9 22 31.0 0.9 1 
2005 70 53 75.7 2.0 16 22.9 0.6 1 
1998–2005 523 372 71.1 1.8 148 28.3 0.7 3 
(a) Percentages are per 100 live births each year. 
(b) Rates are per 10,000 live births.  
 
The outcome of the live births at the end of the neonatal period was available for all but three 
babies. The prevalence of NTD among births was lowest in 2003. The live birth rate was also 
the lowest in this year, but the rates increased again in 2004. The neonatal death rate declined 
slightly during the period 1998–2005 (Table 1.2). Of all births with NTD, 39.4% survived at 
least until the end of the neonatal period (28 days).  
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Characteristics of births with neural tube defects 
Australia 1998–2005 
Sex 
On average, the rates of male and female births with NTD were similar between 1998 and 
2005, but there were slight fluctuations in some years (Figure 2). The average rates were also 
similar for both live births and fetal deaths with NTD. However, the neonatal death rate was 
slightly higher for males than for females, leaving more female babies alive at the end of the 
neonatal period. There were 52% females and 48% males among the babies who survived at 
least 28 days. Nevertheless, female predominance among NTD has been shown in other 
countries. There were 2.4% births with indeterminate sex (Table 1.3).  
Table 1.3: Sex of the births with NTD and the outcome, Australia, 1998–2005 
 Sex   Total births *Fetal deaths Live births Alive on day 28(a)Neonatal deaths(a) 
Male Number 473 212 261 179 81 
 Per cent 49.8 50.4 49.9 48.1 54.7 
 Rate(b) 4.5 2.0 2.5 1.7 0.8 
       
Female Number 454 198 256 193 63 
 Per cent 47.8 47.0 48.9 51.9 42.6 
 Rate(c) 4.6 2.0 2.6 2.0 0.6 
       
Number 17 11 6 0 4 Indeterminate or  
not stated 
Per cent 2.4 2.6 1.1 0.0 2.7 
       
Total Number 944 421 517 372 148 
 Per cent 100 100 100 100 100 
(a) Rates are per 10,000 live births in each group. 
(b) Rates are per 10,000 male births. 
(c) Rates are per 10,000 female births. 
 *  Stillbirths and pregnancy terminations of at least 20 weeks gestation are included in fetal deaths. 
0.0
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       Figure 2: Babies born with NTD by sex, rates per 10,000 births, Australia, 1998–2005 
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Gestational age 
 
About 47% of the births with NTD occurred at less than 32 weeks gestation, and 82.4% of 
these were fetal deaths. The large proportion of fetal deaths in this gestational age group 
indicates a large number of terminations of pregnancy after 20 weeks gestation (Figure 3). Of 
the remaining 17.6% (n: 78) of live births in this less than 32 weeks gestational age group, only 
11.5% (n: 9) survived to the end of the neonatal period. The prevalence of NTD among births 
that occurred before 32 weeks gestation was 133.6 per 10,000 births, but the prevalence of live 
births with NTD was 23.5 per 10,000 births. The neonatal death rate among these very preterm 
babies was 20.8 per 10,000 births (Table 1.4). There were more male births than female births 
(226 versus 205) in this gestational age group.  
Among the births that occurred between 32 and 36 weeks gestation, 79.8% were live births 
and 54.2% of them were alive on day 28. Of all the babies born before 36 weeks gestation, only 
9.9% survived until the end of the neonatal period (Table 1.4).  
About 41% (n: 385) of the births with NTD were born at term and 91.9% (n: 354) were live 
births. By day 28, 88.7% (n: 314) of those babies were still alive (Table 1.4).  
As all babies born at less than 32 weeks gestation are treated in level 3 neonatal intensive care 
units in Australia and some of the other babies born alive with NTD may require assisted 
ventilation or surgery, a considerable number of babies who survive with NTD may require 
management in intensive care units. 
 
 
 
      Figure 3: Outcome of births with NTD by gestation (weeks) at birth, Australia, 1998–2005 
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Table 1.4: Gestational age of the births(a) with NTD and the outcome, Australia, 1998–2005 
Gestational age group Total births **Fetal deaths Live births Alive on day 28 Neonatal deaths 
20–31 Number 443 365 78 9 69 
 Per cent 46.9 86.7 14.9 2.4 46.6 
 Rate(b) 133.6 110.0 23.5 *2.7 *20.8 
       
32–36 Number 104 21 83 45 38 
 Per cent 11.0 5.0 15.9 12.1 25.7 
 Rate(c) 8.3 1.7 6.6 *3.6 *2.9 
       
≥ 37 Number 385 31 354 314 39 
 Per cent 40.8 7.3 67.7 84.4 26.3 
 Rate(d) 2.1 0.2 1.9 *1.7 *0.2 
       
Unknown Number 12 4 8 4 2 
 Per cent 1.3 1.0 1.5 1.1 1.4 
       
Total Number 944 421 523 372 148 
  Per cent 100 100 100 100 100 
(a) Includes all births and pregnancy terminations with at least 20 weeks gestation or at least 400 g birthweight.  
(b) Rates are per 10,000 of all births at less than 32 weeks gestation. 
(c) Rates are per 10,000 of all births between 32 and 36 weeks gestation. 
(d)  Rates are per 10,000 of all births at term. 
 * Rates are per 10,000 live births. 
**  Fetal deaths include still births and pregnancy terminations with at least 20 weeks gestation. 
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Birthweight 
Birthweight was available for about 75% of births. More than 85% of the births for which 
birthweights were not recorded occurred at less than 25 weeks gestation, indicating these 
could be terminations of pregnancy.  
Birthweight was less than 1500 grams for 21% (n: 198) of all births with NTD and only 28.3% 
(n: 56) of these were live births. The highest neonatal death rate was seen in this birthweight 
group. Only 10 of those very low birthweight babies survived more than 28 days (Table 1.5).  
Of the babies who had a birthweight of 1,500–2,499 grams, 79.8% were born alive and more 
than half (52.7%) of them lived at least 28 days.  
About 38% of babies who were born with NTD were at least 2,500 grams birthweight. Of those 
babies, 94.7% were live births and about 92% of them survived until the end of the neonatal 
period (Table 1.5).  
 
Table 1.5: Birthweight of the babies born with NTD and the outcome, Australia, 1998–2005 
 Birthweight   *All births Fetal deaths Live births Alive on day 28 Neonatal deaths 
<1,500 g Number 198 142 56 10 46 
 Per cent 21.0 33.7 10.7 2.7 31.1 
 Rate(a) 65.5 46.9 18.5 3.3 15.2 
       
1,500–2,499 g Number 114 23 91 48 42 
 Per cent 12.1 5.5 17.4 12.9 28.4 
 Rate(b) 10.6 2.1 8.5 4.5 3.9 
       
≥2,500 g Number 357 19 338 311 27 
 Per cent 37.8 4.5 64.6 83.6 18.2 
 Rate(c) 1.9 0.1 1.8 1.6 0.1 
       
Unknown Number 275 237 38 3 33 
 Per cent 29.1 56.3 7.3 0.8 22.3 
       
Total Number 944 421 523 372 148 
  Per cent 100 100 100 100 100 
(a) Rate is per 10,000 of all births with less than 1500 g birthweight. 
(b) Rate is per 10,000 of all births with 1500–2499 g birthweight. 
(c) Rate is per 10,000 of all births with at least 2500 g birthweight. 
 *       All live births and fetal deaths including terminations of pregnancy with at least 20 weeks gestation or at least 400 g birthweight. 
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Plurality 
The rate of NTD was more than five times higher among multiple births compared with 
singleton births (23.7 per 10,000 versus 4.4 per 10,000 births). This difference was statistically 
significant (PR=5.4, 95% CI 4.3–6.8). More singletons were alive at birth than multiple births. 
About 68% of multiple births were fetal deaths.  
More singleton babies who were born alive survived at least to the end of their neonatal 
period compared with babies from multiple births (89% versus 80%). The risk of neonatal 
death was higher in multiple births affected with NTD than in singleton births. 
In 2004 and 2005, the number of women who had affected multiple births was lower than in 
the period 1998–2003, whereas the number of women who had affected singleton births 
increased during this period. The prevalence of affected multiple births declined from average 
26.8 per 10,000 in 1998–2003, to 12.6 per 10,000 multiple births in 2004–2005.  
 
Table 1.6: Outcome of births with NTD by plurality, Australia, 1998–2005 
 Outcome   Singleton Multiple 
Number 866 78 
*Total births 
Rate(a) 4.4 23.7 
    
Number 396 25 
Per cent(b) 45.7 32.1 Live births 
Rate(a) 2.0 7.6 
    
Number 470 53 
Per cent(b) 54.3 67.9 **Fetal deaths 
Rate(a) 2.4 16.1 
    
Number 352 20 
Per cent(c) 88.9 80.0 Alive on day 28 
Rate(d) 1.8 0.1 
(a)  Rates are per 10,000 live births and stillbirths of at least 20 weeks gestation or at least 400 g birthweight 
in each group.  
(b) Percentage of all births. 
(c) Percentage of all live births.  
(d) Rates are per 10,000 live births. 
 *  Total births include live births, stillbirths and terminations of pregnancy with at least 20weeks gestation 
or at least 400 g birthweight.  
** Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
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Characteristics of women who gave birth to babies 
with neural tube defects, Australia, 1998–2005 
The births in this report include live births, stillbirths and terminations of pregnancy of at least 
20 weeks gestation or at least 400 grams birthweight.  
From 1998 to 2005, there were 944 women who gave birth or terminated a pregnancy affected 
with a NTD (rate 4.7 per 10,000 women who gave birth) of at least 20 weeks gestation or at 
least 400 grams birthweight (Table 1.7). The number of women who had a live birth with an 
NTD was 523 (rate 2.6 per 10,000 women who gave birth). This is equivalent to 55% of women 
who had affected births (Table 1.8). There was a slight reduction in the rate of affected women 
until 2003, but the rate increased again in 2004 (Table 1.7). The rate of fetal deaths among 
affected women did not change during this period.  
Women’s age  
A higher rate of pregnancies affected with NTD was seen among younger women compared 
with older women. About 83% of the affected births were seen in women less than 35 years of 
age (Table 1.7). 
There was a reduction in NTD-affected birth rates in teenage women from 1999 to 2003, but 
the rate increased again in 2004. Women in the 20–24 year age group had a lower rate only in 
2002. The rates did not change markedly for women of other age groups (Table 1.7).  
However, the average rate was higher for women less than 30 years of age than for women 
aged 30 years or more (5.3 per 10,000 versus 4.0 per 10,000). This difference was statistically 
significant (PR=1.3, 95% CI 1.1–1.5). 
Table 1.7: Number of women who gave birth(a) at 20 weeks gestation or later by age group and year 
of birth, Australia, 1998–2001 
Women’s age 1998 1999 2000 2001 2002 2003 2004 2005 Total 
<20 8 11 7 7 5 3 10 6 57 
20–24 23 22 33 29 14 19 26 30 196 
25–29 55 35 24 32 30 30 34 32 272 
30–34 25 29 31 25 42 32 33 38 255 
≥35 14 18 23 17 17 18 21 24 152 
Not stated 1 2 1 1 1 0 3 1 10 
Total 126 117 119 111 110 103 127 131 944 
(b)Rate / 10,000 births 
<20 6.4 9.1 5.8 5.9 4.3 2.8 9.0 5.3 6.1 
20–24 5.6 5.6 8.6 7.6 3.8 5.2 7.2 7.8 6.4 
25–29 6.8 4.4 3.1 4.3 4.2 4.3 5.0 4.5 4.6 
30–34 3.4 3.8 4.0 3.1 5.1 3.8 3.9 4.2 3.9 
≥35 3.6 4.2 5.4 3.9 3.8 3.8 4.3 4.4 4.2 
All women 5.1 4.7 4.8 4.5 4.3 4.0 5.0 4.8 4.7 
(a)  Births include all live births and stillbirths and pregnancy terminations of at least 20 weeks gestation or at least 400 g birthweight. 
(b) Rates are per 10,000 women who gave birth. 
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Women aged less than 30 years had a higher rate of NTD-affected live births than older 
women, and more babies born to women of this age group survived at least until the end of 
the neonatal period. The neonatal death rate was highest among births to teenage women. 
Women aged 40 years or more had the lowest rate of babies alive at the end of neonatal 
period. The neonatal death rate for women aged 40 years or more was similar to women 
younger than 25 years of age (Table 1.8). 
Table 1.8: Outcome of live births(a) with NTD by women’s age group, Australia, 1998–2005 
 Women’s age Live births  Alive on day 28  Neonatal deaths 
(years) Number Rate(b) Number Per cent Rate(b) Number Per cent Rate(b) 
<20 29 3.1 19 65.5 2.0 10 34.5 1.1 
20–24 105 3.4 76 72.4 2.5 29 27.6 1.0 
25–29 155 2.6 112 72.3 1.9 42 27.1 0.7 
30–34 142 2.2 102 71.8 1.6 40 28.2 0.6 
35–39 74 2.4 56 75.7 1.8 18 24.3 0.6 
≥40 13 2.2 7 53.8 1.2 6 46.2 1.0 
Not known 5 .. 0 .. .. 0 .. .. 
Total 523 2.6 372 71.1 1.9 148 28.3 0.7 
(a)  Includes all live births of at least 20 weeks gestation or at least 400 g birthweight. 
(b) Rates are per 10,000 women in each age group who gave birth. 
Many women with NTD-affected pregnancies delivered before 32 weeks of gestational age 
(46.9%). About 56% of the women who gave birth before 32 weeks were less than 30 years of 
age (Table 1.9). The rate of delivery at less than 32 weeks was high for all age groups of 
women. The number of teenage women who gave birth at 32–36 weeks was very small and 
not presented in the table. As terminations of pregnancy at or later than 20 weeks were 
included as births, some of these births could be late terminations. Of the 40.8% (n: 385) 
women who gave birth at term, 53.0% were less than 30 years of age (Table 1.9). Poor 
antenatal care, lack of awareness on periconceptional folate use and unplanned pregnancy 
could be some reasons for higher rates of NTD and late terminations in younger women. 
The rate of NTD among multiple births was higher than the NTD rate among singleton births 
for each age group. Among multiple births the rate was highest in the 20–24 year age group.  
Table 1.9: Women who had NTD-affected births(a) by age group and gestation at delivery 
 Women’s age  <32 weeks  32–36 weeks ≥37 weeks 
 (years) Number Rate(b) Number Rate(b) Number Rate(b) 
Gestation 
not 
stated 
<20 34 151.0 n.p. 3.2 20 2.4 1 
20–24 96 192.2 29 16.0 70 2.5 1 
25–29 120 155.9 35 10.9 114 2.0 3 
30–34 115 138.1 26 7.6 112 1.8 2 
≥35 75 126.4 12 5.3 66 2.0 1 
Not known 3 .. 0 .. 3 .. 4 
(a)    All live births and fetal deaths including terminations of pregnancy with at least 20 weeks gestation or at least 400 g birthweight. 
(b)   Rates are per 10,000 women in each age group who gave birth. 
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Indigenous status 
Indigenous women were at higher risk of births affected with NTD than non-Indigenous 
women (9.1 versus 4.4). This difference was statistically significant (PR=2.1, 95% CI 2.0–2.2). 
About 56% of births among both groups were live births. Indigenous babies with NTD are 
more likely to be alive on day 28, but also have two-fold higher risk of neonatal death than 
non-Indigenous babies (Table 1.10). About 75% of Indigenous women who had NTD-affected 
births were less than 30 years old, whereas only about 54% of affected non-Indigenous women 
were in this age group. The risk of having an NTD-affected pregnancy was similar among 
teenage women, but the risk increased more than two-fold with increasing maternal age in 
Indigenous women. Non-Indigenous women had a decreasing risk with increasing age (Table 
1.10). 
Table 1.10: Characteristics of women who gave birth(a) by Indigenous status, 1998–2005, Australia 
Indigenous  Non-Indigenous  Unknown Total   
 Number Per cent(b) Rate(c) Number Per cent(b) Rate(c) Number Number 
Status of the baby        
Live births 36 56.3 5.1 482 55.9 2.5 5 523 
**Fetal deaths 28 43.8 4.0 381 44.1 1.9 12 421 
*Total births 64 100.0 9.1 863 100.0 4.4 17 944 
Outcome of the baby       
Alive on day 28 24 66.7 3.4 345 71.6 1.8 3 372 
Neonatal deaths 12 42.9 1.7 134 27.8 0.7 2 148 
Not stated 0 .. .. 4 0.6 .. 0 4 
Women’s age (years)       
<20 8 12.5 5.1 48 5.6 6.1 1 57 
20–24 23 35.9 10.5 169 19.6 6.0 4 196 
25–29 17 26.6 9.7 250 29.0 4.4 5 272 
30–34 10 15.6 9.5 243 28.2 3.8 2 255 
≥35 6 9.4 12.1 145 16.8 4.1 3 154 
Not stated 0 .. .. 8 0.9 .. 2 10 
Gestational age at delivery (weeks)      
<32 31 48.4 128.2 403 46.7 131.9 9 443 
32–36 13 20.3 16.2 88 10.2 7.5 3 103 
≥37 19 29.7 3.1 362 41.9 2.0 4 385 
Not stated 1 1.6 .. 10 1.2 .. 1 12 
Plurality         
Singleton 56 87.5 8.0 796 92.2 4.2 13 866 
Multiple 8 12.5 99.1 67 7.8 21.1 3 78 
(a)  Includes all live births, stillbirths and pregnancy terminations of at least 20 weeks gestation or at least 400 g birthweight. 
(b) Percentages are per 100 women who gave birth in each group by Indigenous status. 
(c)  Rates are per 10,000 women who gave birth in each group by Indigenous status. 
 *  Total births include live births, stillbirths and terminations of pregnancy with at least 20weeks gestation or at least 400 g birthweight.  
** Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
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Indigenous women were more likely to give birth after 31 weeks gestation compared with 
non-Indigenous women. Indigenous women who had multiple births had a higher rate of 
NTD-affected births compared with non-Indigenous women who had multiple births. These 
data show a decreasing trend of NTD-affected births among Indigenous women, but this 
could be due to under-reporting of Indigenous status from some states and territories  
(Figure 4).  
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      Figure 4: Rate of NTD by Indigenous status, 1998–2005, Australia  
 
Remoteness of the women’s residence 
Table 1.11: Remoteness of the residence of women who had NTD-affected 
births(a), 1998–2005, Australia 
Area of Remoteness Number Per cent Rate(b) 
Major cities 565 66.6 4.3 
Regional areas 245 28.9 4.3 
Remote areas 38 4.5 7.7 
(a) Includes all live births, stillbirths and pregnancy terminations of at least 20 weeks gestation or  
at least 400 g birthweight. 
(b) Rate is per 10,000 women who gave birth in each area of remoteness. 
The remoteness of the area of residence of women who gave birth to a baby with NTD was 
available for 848 women (89.8% affected women). Two-thirds of the women who gave birth to 
a baby with an NTD lived in major cities. The proportion of women who lived in remote areas 
and had a birth with NTD was very small. Nevertheless, these women were more likely to 
have a birth affected with NTD (Table 1.11). The difference between women who lived in 
major cities and remote areas and the difference between women who lived in regional areas 
and remote areas were statistically significant (PR = 1.8, 95% CI 1.6–2.0).  
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All neural tube defects among births and 
terminations of pregnancy  
These data were provided from birth defect registers of New South Wales, Victoria, South 
Australia and Western Australia. The data include early terminations of pregnancy 
(gestational age less than 20 weeks), late terminations of pregnancy of at least 20 weeks 
gestation and all births including live births and stillbirths. These states collect data from 
multiple sources, and the duration of collection differs from state to state; Victoria collects 
data up to the age of 15 years; Western Australia up to the age of 6 years; South Australia up 
to the age of 5 years and New South Wales up to 1 year. Because most neural tube defects are 
obvious at birth, the numbers of defects at birth from these four states are expected to be 
almost complete. Spina bifida occulta, which is a mild form of NTD and not obvious at birth is 
not included in this report. However, there may be some missing data on terminations of 
pregnancy before 20 weeks gestation. The largest proportion of missing data is expected to be 
from New South Wales where the largest number of births occurs, which is equivalent to  
one-third of births in Australia.   
Every year, more than 75% of the births in Australia occur in these four states, and the states 
cover a wide range of geographical areas, all ethnic groups living in Australia, different 
socioeconomic status and various environments. Studies have shown evidence of the 
relationship between these factors and the occurrence of NTD. Therefore, an estimated overall 
prevalence rate for NTD was calculated on the data provided by these four states. All rates 
given in this section include live births, stillbirths and terminations of pregnancy at all 
gestations. The denominators include only live births and fetal deaths from these four states, 
because the total number of terminations is not known. Detailed data for NTD were not 
available for the period 1992–1997 for all four states. Therefore, only the number and 
prevalence up to 1998 are presented in this report. 
 
Prevalence 
In 1992 the overall estimated NTD rate based on the data from four states was 15.0 per 10,000 
pregnancies. This rate slightly decreased in 1993 and 1994, but increased again in 1995. The 
highest prevalence between 1992 and 2005 was seen in 1995 and the lowest prevalence was in 
2003. The decline in the rate of NTD-affected pregnancies from 1995 to 2003 was 37.4%. 
Between 1992 and 2005, there was a 32.7% decline in the estimated prevalence of NTD in these 
four states. However the decline between 1998 and 2005 was only 10.6%. A major decline 
occurred until 1998 (Figure 5, Table 2.1). 
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       Figure 5: Estimated prevalence (per 10,000 live births and stillbirths) and confidence intervals of    
all NTD including all births and terminations of pregnancy, NSW, Vic, SA and WA, 1992–2005  
 
Table 2.1: Total number of NTD(a) by year of pregnancy, NSW, Vic,  
SA and WA, 1992–2005 
 Year Number Rate(b) 95% CI 
1992 301 15.0 13.3–16.8 
1993 284 14.4 12.7–16.1 
1994 281 14.2 12.6–16.0 
1995 305 15.5 13.9–17.4 
1996 256 13.2 11.6–14.9 
1997 259 13.3 11.8–15.1 
1998 218 11.3 9.9–13.0 
1999 230 11.8 10.4–13.5 
2000 220 11.4 9.9–13.0 
2001 204 10.7 9.2–12.2 
2002 190 9.9 8.6–11.4 
2003 186 9.7 8.3–11.2 
2004 205 10.7 9.2–12.2 
2005 205 10.1 8.8–11.6 
(a) Includes live births, stillbirths and terminations of pregnancy at all gestational ages. 
(b) Rates are per 10,000 live births and stillbirths. 
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Outcomes of the pregnancies and available characteristics of women who had pregnancies 
affected with NTD were provided by four states for the period 1998–2005. 
Each year, during the period 1998–2005, at least 50% of pregnancies with NTD were 
terminated before 20 weeks gestation. This demonstrates that the collection of termination of 
pregnancy data for all gestations is essential to estimate the accurate prevalence of NTD. From 
1998 to 2005, more than 77% of pregnancies with NTD were managed by terminations or 
resulted in stillbirths. The lowest NTD-affected live birth rate was in 2003 and has increased 
again in 2004. However, the fetal death rate increased by 17.9% from 1998 to 2005, probably 
due to increased terminations of pregnancy after 20 weeks of gestation. A decline (22.2%) in 
terminations of pregnancies before 20 weeks gestation was seen during the period 1998 to 
2005. The lowest overall estimated NTD prevalence was seen in 2003 (Table 2.2). 
Between 1998 and 2005, 23% of the NTD-affected pregnancies were live births and 71% of 
those babies were alive on day 28 (rate 1.8 per 10,000 pregnancies). The proportion of babies 
alive by the end of the neonatal period decreased until 2002 and increased again in 2003. The 
neonatal death rate has not changed markedly since 1998 (Table 2.3). 
Table 2.2: All pregnancies affected with NTD by outcome, NSW, Vic, SA, and WA, 1998–2005 
 Live births  **Fetal deaths  TOP <20 weeks  All NTD 
Year Number  Rate(a) Number Rate(a) Number Rate(a) Number Rate(a) 
1998 51 2.6 45 2.3 122 6.3 218 11.4 
1999 50 2.6 40 2.1 140 7.2 230 11.8 
2000 54 2.8 39 2.0 127 6.6 220 11.4 
2001 46 2.4 49 2.6 109 5.7 203 10.6 
2002 43 2.2 46 2.4 101 5.3 190 9.9 
2003 37 1.9 47 2.4 102 5.3 186 9.7 
2004 53 2.8 50 2.6 102 5.3 205 10.7 
2005 48 2.4 57 2.8 100 4.9 205 10.1 
(a) Rates are per 10,000 live births and stillbirths. 
** Fetal deaths include stillbirths and pregnancy terminations of at least 20 weeks gestation. 
Table 2.3: Outcomes of the live births with NTD by year of birth, NSW, Vic, SA, and WA, 1998–2005 
 Live births  Alive on day 28  Neonatal deaths 
 Year Number Rate(a) Number Per cent Rate(b) Number Per cent Rate(b) 
1998 51 2.6 37 72.5 1.9 14 27.5 0.7 
1999 50 2.6 37 74.0 1.9 13 26.0 0.7 
2000 54 2.8 41 75.9 2.1 13 24.1 0.7 
2001 46 2.4 31 67.4 1.6 15 32.6 0.8 
2002 43 2.2 27 62.8 1.4 16 37.2 0.8 
2003 37 1.9 25 67.6 1.3 12 32.4 0.6 
2004 53 2.8 36 67.9 1.9 17 32.1 0.9 
2005 48 2.4 36 75.0 1.8 12 25.0 0.6 
1998–2005 382 2.5 270 70.7 1.8 112 29.3 0.7 
(a) Rates are per 10,000 live births and stillbirths. 
(b) Rates are per 10,000 live births. 
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The proportion of terminations of pregnancy before 20 weeks gestation was nearly three-fold 
higher than the fetal deaths and live births during the period 1998 to 2005. However, the 
proportion of early pregnancy terminations showed a mild reduction more recently (Figure 6).   
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Figure 6: Proportion of terminations of pregnancy before 20 weeks gestation (TOP), *fetal          
deaths and live births, NTD in NSW, Vic, SA and WA, 1998–2005 
Plurality 
Plurality status was available for 95.5% of the data. The rate of NTD-affected singleton 
pregnancies has not changed significantly during the eight year period. However the rate of 
NTD-affected multiple pregnancies had declined. The lowest rate for multiple pregnancies 
was seen in 2001 (Table 2.4). The data show that the multiple pregnancies had approximately 
three times higher rate than the singleton pregnancies. This difference was statistically 
significant (PR=2.7, 95% CI 2.5–2.9).  
Table 2.4: Plurality and year of pregnancy NSW, Vic, SA, and WA, 1998–2005 
Year  Singleton Rate(a) Multiple Rate(b) Prevalence ratio 
1998 209 8.9 8 22.5 2.5 
1999 214 9.1 16 43.3 4.8 
2000 208 8.8 12 31.1 3.5 
2001 200 8.6 4 10.2 1.2 
2002 180 7.7 10 24.8 3.2 
2003 175 7.5 11 27.3 3.7 
2004 200 8.5 5 12.5 1.5 
2005 198 8.0 6 13.9 1.8 
1998–2005 1584 8.4 72 22.9 2.7 
(a) Rates are per 10,000 women who gave birth to singleton pregnancies and year of birth. 
(b) Rates are per 10,000 women who gave birth to10,000 multiple pregnancies and year of birth. 
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Characteristics of women who had pregnancies 
affected with neural tube defects  
Age 
Age of the women was available for 99.5% who had a pregnancy affected with NTD in the 
four states. Although there were fluctuations in the rates, women less than 30 years of age had 
a higher rate of NTD-affected pregnancies than women aged 30 years or more. On average, 
teenage women had the highest rate. The rate of affected pregnancies decreased with 
increased age of women. However, the lowest rate was seen in women aged 30–34 years.  
 
Table 2.5: All NTD, women’s age group by year of pregnancy, NSW, Vic, SA and WA, 1998–2005 
Women’s age  1998 1999 2000 2001 2002 2003 2004 2005 Total 
<20 14 14 8 14 4 5 13 10 82 
20–24 32 38 49 35 23 22 26 33 258 
25–29 90 77 56 64 57 58 59 48 509 
30–34 50 56 62 48 67 62 59 60 464 
≥35 25 38 41 34 33 34 42 48 295 
Not stated 7 7 4 9 6 5 6 6 50 
Total 218 230 220 204 190 186 205 205 1658 
Rate(a)/10,000 births 
<20 16.2 16.2 9.7 17.3 5.0 6.7 17.3 13.0 12.7 
20–24 10.8 13.1 17.6 12.8 8.6 8.3 10.1 12.2 11.7 
25–29 14.5 12.6 9.4 11.5 10.6 11.1 11.6 9.1 11.4 
30–34 8.6 9.4 10.2 7.8 10.4 9.4 8.9 8.7 9.2 
≥35 8.0 11.7 12.1 10.0 9.3 9.2 10.9 11.3 10.3 
(a) Rates are per 10,000 women who gave birth each year by maternal age group. 
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In recent years, women less than 30 years of age had a decreasing rate of affected pregnancies, 
while the rate for older women did not decline markedly (Table 2.5, figure 7). The average rate 
for women less than 30 years of age was 11.6/10,000 while the average rate for women aged 
30 years or more was 9.5/10,000. The difference in two age groups was statistically significant 
(PR=1.2, CI 1.1–1.3).  
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       Figure 7: Rates of pregnancies with NTD, by maternal age group and year, NSW, Vic, SA, and 
WA, 1998–2005   
 
Remoteness of the women’s residence 
Approximately 83% of the records of women who had a pregnancy affected with NTD had 
data on remoteness of the area of residence. Of those women, 96.8% lived in major cities or 
regional areas (Table 2.6). Only a small proportion of affected women lived in remote areas, 
but they had a higher rate of NTD-affected pregnancies than the women living in cities or 
regional areas. The difference was statistically significant (PR=1.5, 95% CI 1.4–1.7). This 
suggests that women living in remote areas are more likely to have a pregnancy affected with 
NTD. 
Table 2.6: Remoteness of residence of women who had NTD-affected pregnancies                              
NSW, Vic, SA, and WA, 1998–2005 
Area of remoteness Number Per cent Rate(a) 
Major cities 998 72.5 8.8 
Regional areas 334 24.3 8.7 
Remote areas 44 3.2 13.5 
(a) Rates are per 10,000 women who gave birth. 
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Indigenous status 
Indigenous status of the women was available for 98% of the births in these four states, but 
only 35.3% of the women who had terminations of pregnancy before 20 weeks had Indigenous 
status reported. Therefore, overall proportion of women who had their Indigenous status 
recorded was 64% (n: 1059). 
According to the available data, Indigenous women were 2.4 times more likely to have a  
NTD-affected pregnancy than the non-Indigenous women (PR =2.4, 95% CI 2.2–2.6). These 
data show that less than one-fifth of the Indigenous women had a termination of pregnancy 
before 20 weeks gestation if the fetus had a NTD, whereas almost one-third of non-Indigenous 
women had early terminations if they had an NTD-affected pregnancy. Over 80% of affected 
Indigenous women either had delivered a baby or had terminations at or after 20 weeks of 
gestation. Nearly half of Indigenous women had given birth between 20 and 31 weeks of 
gestation, which could include late terminations of pregnancy. Indigenous women were more 
likely to give birth at term than non-Indigenous women (Table 2.7). 
About 74% of the affected Indigenous women were less than 30 years of age, whereas only 
about 53% of the non-Indigenous women were younger than 30 years. However, the rates 
were similar for teenage women in both groups. With advancing age, the rates were 
decreasing in non-Indigenous women, while the rates did not change markedly in Indigenous 
women (Table 2.7). 
Table 2.7: Characteristics of women who had pregnancies affected with NTD by Indigenous status,  
NSW, Vic, SA, and WA, 1998–2005 
  Indigenous  Non-Indigenous 
  Number Per cent(a) Rate(b) Number Per cent(a) Rate(b) 
Outcomes   
*TOP <20 10 17.2 2.7 310 31.0 2.1 
Live births 24 41.4 6.6 354 35.4 2.4 
Fetal Deaths 24 41.4 6.6 337 33.7 2.3 
Total 58 100.0 15.9 1001 100.0 6.7 
Gestational age (weeks)      
<20 10 17.2 .. 310 31.0 .. 
20–31 25 43.1 215.3 351 35.1 172.7 
32–36 9 15.5 24.5 65 6.5 8.2 
≥37 13 22.4 4.1 270 27.0 0.1 
Not known 1 1.7 .. 5 0.5 .. 
Women’s age group (years)     
<20 7 12.1 8.6 51 5.1 9.1 
20–24 19 32.8 16.6 172 17.2 8.2 
25–29 17 29.3 18.8 309 30.9 7.0 
30–34 10 17.2 18.2 287 28.7 5.7 
≥35 4 6.9 15.3 168 16.8 5.9 
Not known 1 1.7 .. 14 1.4 .. 
(a) Percentages are per 100 women in each group. 
(b) Rates are per 10,000 all births in each group. 
 *        Termination of pregnancy at less than 20 weeks gestation. 
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    Figure 8: Indigenous status of women affected with NTD by year of birth or terminations of     
pregnancy, NSW, Vic, SA and WA, 1998–2005 
 
The data show that the decreasing trend of NTD is only seen among non-Indigenous women; 
there is no change among Indigenous women (Figure 8). 
A study in Western Australia has shown a widening gap and disparity among Indigenous and 
non-Indigenous infants who were affected with NTD (Bower et al. 2004C). According to this 
study, the prevalence of NTD has declined by 30% among non-Indigenous women, but there 
was no decline among Indigenous women. 
About 60% of the data on Indigenous women who had a pregnancy affected with NTD among 
the four states are from Western Australia, while none or few affected pregnancies were 
reported from other states. Therefore it may not be appropriate to apply the above finding 
across the country because of a large number of missing data on Indigenous status. 
Nevertheless, rates among births showed a decreasing trend of NTD in Indigenous women 
(Figure 4). Those data represent 55% Indigenous NTD-affected births from states other than 
Western Australia. The early terminations are low among Indigenous people. Therefore birth 
rates may be more representative of prevalence of NTD among Indigenous women (Figure 4).  
The availability of data from Northern Territory, termination of pregnancy data from all states 
and the paternal Indigenous status would provide more accurate information on NTD in the 
Indigenous population. 
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Prevalence of neural tube defects among 
births by individual states 
The national data show that the birth prevalence is not equivalent across all states. Western 
Australia, South Australia and Victoria, where data ascertainment is near complete, have 
higher rates of NTD than the other states. These three states and New South Wales collect data 
from multiple sources and continue to collect data after the birth episode, with New South 
Wales collecting for the shortest duration, which is at least up to one year. South Australia 
showed a marked decline in the NTD prevalence in recent years, while Western Australia 
showed a sudden increase in births with NTD in 2004, probably due to increased termination 
of pregnancy after 20 weeks gestation. New South Wales has the largest proportion of births 
in Australia, but has lower rates of NTD-affected births than expected for each year. This may 
show an incomplete ascertainment of data. 
Queensland, where data were collected only during the birth episode, had the lowest 
prevalence. The data on some late terminations due to NTD and mild forms of spina bifida 
may be missing as a result of collecting data only during the birth episode. In 2004 and 2005, 
the rates in Queensland have increased, which could be partly due to better ascertainment of 
data. Tasmania and the Australian Capital Territory also collect data only during the birth 
episode and have only a small number of NTD-affected births. 
 
 
0
2
4
6
8
10
12
1998 1999 2000 2001 2002 2003 2004 2005
Year
Rate/10,000
NSW
Vic
QLD
SA
WA
 
Notes: Rates for Tasmania and the Australian Capital Territory are not included because of small numbers. 
Rates are per 10,000 live births and stillbirths 
. 
Figure 9: Prevalence of NTD among births, by year of birth and state, NSW, Vic, Qld,  
SA and WA, 1998–2005  
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Overall prevalence of NTD in four states providing information 
including termination of pregnancy 
New South Wales, Victoria, South Australia and Western Australia have shown an obvious 
decline in the prevalence of all NTD, including live births, stillbirths and terminations of 
pregnancy at all gestational ages, since 1992 (Figure 10). 
Reporting data on all congenital anomalies, including terminations of pregnancy at less than 
20 weeks gestation is mandatory in South Australia. Although there were mild fluctuations, 
South Australian data show a gradual decline in the estimated prevalence during the period 
1992 to 2005. There was a sudden increase in the prevalence in 2000, but it gradually 
decreased again from 2001. South Australia showed a 33% decrease in NTD from 1992 to 2005 
(Table 3.3).  
Western Australia had the highest prevalence of NTD between 1992 and 1995. There was a 
43% decrease in the prevalence between 1995 and 1996. From 1996 to 2003 the rates were 
similar to other states, but increased again in 2004. In 2004 and 2005, Western Australia had 
the highest prevalence among the four sates. The decrease in prevalence between 1992 and 
2005 was 15.5% (Table 3.4).   
In Victoria, between 1992 and 2005, the highest prevalence of NTD was seen between 1995 and 
1997. From 1997 to 2005, there was a 36.3% decline in the prevalence. The decline from 1992 to 
2005 was 20% (Table 3.2). 
Available data from New South Wales also show a gradual decrease in prevalence, but the 
prevalence is lower than expected, when compared with the other three states (Table 3.1). 
New South Wales usually has the highest rate of births in Australia and has a high population 
of Indigenous people as well as people with low socio-economic background. Therefore, the 
prevalence in New South Wales would be expected to be higher than the observed rates. This 
may suggest missing data from this state, in particular, terminations at less than 20 weeks. 
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Figure 10: Prevalence of all NTD, in NSW, Vic, SA and WA, 1992–2005 
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Table 3.1: Number and estimated rate of all  Table 3.2: Number and estimated rate of all 
NTD, New South Wales, 1992–2005   NTD, Victoria, 1992–2005                                                               
 NSW Number Rate(a) 95% CI   VIC Number Rate(a) 95% CI 
1992 112 12.6 10.4–15.1  1992 102 15.4 12.5–18.6 
1993 111 12.7 10.4–15.2  1993 96 14.8 12.0–18.1 
1994 86 9.8 7.8–12.1  1994 110 16.9 13.9–20.4 
1995 83 9.5 7.6–11.8  1995 123 19.3 16.0–23.0 
1996 81 9.4 7.4–11.7  1996 112 17.8 14.7–21.4 
1997 72 8.2 6.4–10.3  1997 120 19.3 16.0–23.0 
1998 76 8.8 6.9–11.0  1998 78 12.6 9.9–15.7 
1999 77 8.8 7.0–11.0  1999 89 14.2 11.4–17.5 
2000 68 7.7 6.0–9.8  2000 78 12.5 9.9–15.6 
2001 64 7.5 5.7–9.5  2001 78 12.6 9.9–15.7 
2002 58 6.7 5.1–8.7  2002 75 11.9 9.3–14.9 
2003 60 6.9 5.3–8.9  2003 79 12.4 9.8–15.5 
2004 54 6.3 4.7–8.2  2004 86 13.5 10.8–16.7 
2005 56 6.2 4.7–8.0  2005 82 12.3 9.8–15.3 
(a) Rates are per 10,000 live births and stillbirths in NSW.     (a) Rates are per 10,000 live births and stillbirths in Vic. 
 
Table 3.3: Number and estimated rate of all   Table 3.4: Number and estimated rate of all 
NTD, South Australia, 1992–2005     NTD, Western Australia, 1992–2005  
SA Number Rate(a) 95% CI   WA Number Rate(a) 95% CI 
1992 38 18.9 13.3–25.9  1992 49 19.3 14.3–25.6 
1993 32 16.0 11.1–22.6  1993 45 17.8 13.0–23.7 
1994 30 15.2 10.2–21.6  1994 55 21.6 16.3–28.1 
1995 37 18.9 12.9–25.4  1995 63 24.8 19.0–31.7 
1996 27 14.1 9.3–20.5  1996 36 14.1 9.9–19.5 
1997 32 17.1 11.7–24.2  1997 35 13.9 9.6–19.3 
1998 29 15.5 10.4–22.2  1998 35 13.6 9.5–19.0 
1999 21 11.3 7.0–17.3  1999 43 16.7 12.1–22.5 
2000 32 17.9 12.3–25.3  2000 42 16.6 12.0–22.5 
2001 27 15.3 10.1–22.2  2001 35 14.0 9.8–19.5 
2002 23 13.0 8.2–19.4  2002 34 13.7 9.5–19.2 
2003 21 11.8 7.3–18.0  2003 26 10.5 6.9–15.4 
2004 20 11.4 7.0–17.6  2004 45 17.6 12.9–23.6 
2005 23 12.6 8.0–19.0  2005 44 16.3 11.9–21.9 
(a) Rates are per 10,000 live births and stillbirths in SA.     (a) Rates are per 10,000 live births and stillbirths in WA. 
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Estimated prevalence of NTD based on data 
from Victoria, South Australia and Western 
Australia 
The data from three states (Victoria, South Australia and Western Australia) that have nearly 
complete ascertainment, including terminations of pregnancy before 20 weeks of gestation 
were used to calculate the estimated rate. As shown in Table 3.1 and Figure 10, New South 
Wales has low rates for all years because of missing data, mainly on some terminations of 
pregnancy. Therefore, New South Wales data were not used to compute the estimated 
prevalence.  
Prevalence 
When overall estimated NTD rates were calculated using data from Victoria, South Australia 
and Western Australia, these rates were about 3.5 per 10,000 pregnancies higher than the rates 
observed using the data from four states that include New South Wales (Figure 11). Data from 
the three states also show an obvious decreasing trend in NTD-affected pregnancies from 1992 
to 2005 (Figure 12). Studies have shown that ascertainment of data on NTD are near complete 
in these three states. Therefore, prevalence based on these three states could be a more 
accurate baseline of NTD prevalence prior to mandatory fortification of bread flour with folic 
acid. 
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     Figure 11: Estimated overall prevalence of NTD based on data of three and four states, 1992–2005 
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The data show a 26% decline in NTD prevalence from 1992 to 2005 (Table 4.1). Since the 
confirmation from randomised controlled trials in 1991, of the effect of periconceptional folate 
use in reducing NTD, there have been many health promotion programs in these states to 
increase the knowledge of women and health professionals. Nevertheless, the highest 
prevalence was seen in 1995. With the efforts of many health professionals and others 
interested in NTD, the prevalence has declined by 37.6% from 1995 to 2005. There was a large 
decline (30.0%) in the prevalence from 1997 to 1998. After that the decline in prevalence was 
minimal (Table 4.1). The lowest rate was seen in 2003. The prevalence rose again in 2004 and 
2005, and this increase have been seen across all three states. Western Australia showed the 
highest increase.  
Table 4.1: All NTD reported from Vic, SA and WA by year of birth or  
terminations of pregnancy, 1992–2005  
Year Number  Rate(a) 95% CI 
1992 201 18.0 15.6–20.6 
1993 188 17.1 14.7–19.7 
1994 213 19.3 16.8–22.1 
1995 232 21.3 18.7–24.3 
1996 189 17.6 15.1–20.2 
1997 205 19.3 16.7–22.1 
1998 142 13.3 11.2–15.7 
1999 153 14.3 12.1–16.8 
2000 152 14.4 12.2–16.9 
2001 140 13.4 11.2–15.8 
2002 132 12.5 10.5–14.8 
2003 126 11.9 9.9–14.1 
2004 151 14.1 12.0–16.6 
2005 149 13.3 11.3–15.6 
(a) Rates are per 10,000 live births and stillbirths. 
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Figure 12: Estimated NTD rates in Australia based on data from Vic, SA and WA, 1992–2005 
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In these three states, the prevalence of live births gradually decreased from 1998 to 2003, but 
increased again in 2004 (Table 4.2). More than a quarter of NTD-affected pregnancies were 
alive at birth. About three quarters of those who were alive at birth survived at least until the 
end of the neonatal period (Table 4.3). The live birth rates in three states are not significantly 
higher than the rates observed in four states, except in 1998, suggesting the missing data is 
mainly among pregnancy terminations before 20 weeks gestation (Table 2.3, Table 4.3).  
The neonatal deaths due to NTD in the three states fluctuated during 1998–2005.  
The fetal death rate has gradually increased, possibly due to increased late pregnancy 
terminations. During the eight year period from 1998 to 2005, the highest termination of 
pregnancy (<20 weeks gestation) rate was seen in 1999. From 1999 to 2005 there was a 23.3% 
decrease in the rates of early terminations. 
 
Table 4.2: All neural tube defects by outcome, Vic, SA, and WA, 1998–2005 
 Live births  **Fetal deaths  TOP <20 weeks  All NTD 
Year   Number  Rate(a) Number Rate(a) Number Rate(a) Number  Rate(a) 
1998 38 3.6 20 1.9 84 7.9 142 13.3 
1999 33 3.1 24 2.2 96 9.0 153 14.3 
2000 35 3.3 23 2.2 94 8.9 152 14.4 
2001 27 2.6 33 3.1 80 7.6 140 13.4 
2002 23 2.2 26 2.5 83 7.9 132 12.5 
2003 20 1.9 28 2.6 78 7.4 126 11.9 
2004 31 2.9 38 3.6 82 7.7 151 14.1 
2005 34 3.0 38 3.4 77 6.9 149 13.3 
(a) Rates are per 10,000 live births and stillbirths. 
 ** Fetal deaths include stillbirths and pregnancy terminations of at least 20 weeks gestation. 
 
Table 4.3: All live births with neural tube defects by outcome, Vic, SA, and WA, 1998–2005 
  Live births  Alive on day 28  Neonatal deaths 
 Year Number Rate(a) Number  Per cent Rate(b) Number Per cent Rate(b) 
1998 38 3.6 29 76.3 2.8 9 23.7 0.9 
1999 33 3.1 26 78.8 2.5 7 21.2 0.7 
2000 35 3.3 27 77.1 2.6 8 22.9 0.8 
2001 27 2.6 20 74.1 2.0 7 25.9 0.7 
2002 23 2.2 14 60.9 1.4 9 39.1 0.9 
2003 20 1.9 14 70.0 1.4 6 30.0 0.6 
2004 31 2.9 22 71.0 2.1 9 29.0 0.9 
2005 34 3.0 27 79.4 2.5 7 20.6 0.6 
(a) Rates are per 10,000 live births and stillbirths. 
(b) Rates are per 10,000 live births. 
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Women’s age 
A higher rate of NTD-affected pregnancies was seen mainly in younger age groups. However 
the rates fluctuated each year and the lowest was seen in 2003. The rate of NTD among older 
women has increased in recent years, probably because of the increasing number of older 
women becoming pregnant. The lowest rate was seen among women aged between 30 and 34 
years. When the data from New South Wales, where data are incomplete were excluded, the 
rates were about 3.0 per 10,000 higher in each age group than the rates including NSW (Figure 
13, Table 2.5, Table 4.4).   
 
   
       Figure 13: Rates of NTD by maternal age group when rates were based on three and four states 
 
Table 4.4: All NTD, women’s age group by year of pregnancy, Vic, SA, and WA, 1998–2005 
 Women’s age 1998 1999 2000 2001 2002 2003 2004 2005 Total 
<20 7 8 6 8 3 3 9 6 50 
20–24 20 30 31 23 17 18 21 23 183 
25–29 58 53 42 46 33 41 39 39 351 
30–34 34 35 43 35 49 38 46 40 320 
≥35 20 27 30 26 28 26 35 40 232 
Not stated 3 0 0 2 2 0 1 1 9 
Rate(a) per 10,000         
<20 15.4 19.6 13.6 18.6 6.9 7.7 21.7 14.1 14.7 
20–24 13.0 20.7 21.3 16.0 11.9 13.1 15.3 16.0 15.9 
25–29 17.0 16.3 13.1 15.2 11.4 14.6 14.0 13.6 14.5 
30–34 10.2 10.1 12.5 9.9 13.4 10.1 12.3 10.4 11.1 
≥35 11.5 13.8 16.1 13.8 14.1 12.4 16.1 16.7 14.4 
(a) Rates are per 10,000 women who gave birth each year by maternal age group. 
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Anencephaly 
 
Anencephaly is a congenital anomaly characterised by the total or partial absence of the 
cranial vault and the covering skin. The brain tissue in affected fetuses may be missing or 
reduced to a small mass. Anencephaly in this report includes infants with craniorachischisis, 
iniencephaly and other neural tube defects such as encephalocele or open spina bifida, when 
associated with anencephaly. Acephaly or absence of head observed in amorphous acardiac 
twins was excluded. 
Anencephaly occurs when the cephalic end of the neural tube fails to close, resulting in the 
absence of a major part of the brain, skull, and scalp. The remaining brain tissue is often 
exposed and not covered by bone or skin. This condition is not compatible with life and a 
baby born with anencephaly is usually blind, deaf, unconscious, and unable to feel pain. Some 
individuals with anencephaly may be born with a rudimentary brain stem. They may have 
reflex actions such as breathing and responses to sound or touch. If the anencephaly extends 
to the neck, exposing a thin and flattened spinal cord, this condition is known as 
craniorachischisis. If the head of a fetus with anencephaly and spinal defects is bent 
backwards with the face looking upwards this condition is called iniencephaly. The affected 
infant tends to be short, with a disproportionately large head. 
Prevalence 
There were 216 births of at least 20 weeks gestational age or at least 400 grams birthweight 
diagnosed with anencephaly, reported from all states and territories except Northern Territory 
from 1998 to 2005. About 64% of those births were stillbirths or terminations of pregnancy at 
or after 20 weeks gestation. The rate of live births was highest in 1998 and had an average rate 
of 0.4 per 10,000 births between 1998 and 2005 while the fetal death rate remained 0.7 per 
10,000 births (Table 5.1). The average fetal death rate was about 43% higher than the live 
births. The anencephaly prevalence among births had decreased by 36% from 1998 to 2005. Of 
the 36% of babies who were born alive, all died early in the neonatal period. 
Table 5.1: All anencephaly among births(a), Australia, 1998–2005 
  Live births Rate(b) *Fetal deaths Rate(b) All births Rate(b) 
1998 17 0.7 18 0.7 35 1.4 
1999 8 0.3 15 0.6 23 0.9 
2000 9 0.4 18 0.7 27 1.1 
2001 7 0.3 17 0.7 24 1.0 
2002 12 0.5 21 0.8 33 1.3 
2003 9 0.4 14 0.6 23 0.9 
2004 10 0.4 17 0.7 27 1.1 
2005 6 0.2 18 0.7 24 0.9 
1998–2005 78 0.4 138 0.7 216 1.1 
(a) Includes all live births, stillbirths and pregnancy terminations of at least 20 weeks gestation or at least 400 g birthweight.  
(b) Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
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There were 666 pregnancies affected with anencephaly in the four states including New South 
Wales, Victoria, South Australia and Western Australia (Table 5.2). These data include 
anencephaly-affected terminations of pregnancy at less than 20 weeks during 1998 to 2005. 
About 73% of those pregnancies were managed by early terminations, before 20 weeks 
gestation. Of all those pregnancies, 91.6% resulted in terminations of pregnancy or fetal 
deaths. The 8.4% who were born alive did not survive to the end of the neonatal period (Table 
5.2).  
The rate of termination of pregnancy before 20 weeks gestation due to NTD has declined by 
22.2% from 1998 to 2005. During the same period, the estimated rate of all anencephaly in the 
four states decreased by 21.6%. 
Table 5.2: All anencephaly, including terminations of pregnancy, NSW, Vic, SA, and WA, 1998–2005 
  Live births  *Fetal deaths  **TOP <20 weeks 
  Number Rate(a) Number Rate(a) Number Rate(a) 
All 
anencephaly Rate(a) 
1998 9 0.5 16 0.8 73 3.8 98 5.1 
1999 5 0.3 12 0.6 65 3.3 82 4.2 
2000 7 0.4 18 0.9 59 3.0 84 4.3 
2001 5 0.3 15 0.8 65 3.4 85 4.5 
2002 10 0.5 19 1.0 54 2.8 83 4.3 
2003 8 0.4 13 0.7 53 2.8 74 3.8 
2004 7 0.4 15 0.8 57 3.0 79 4.1 
2005 5 0.2 18 0.9 58 2.9 81 4.0 
1998–2005  56 0.4 126 0.8 484 3.1 666 4.3 
 (a) Rates are per 10,000 live births and stillbirths. 
  * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
 **  TOP – Terminations of pregnancy before 20 weeks gestation. 
 
 
When the data from New South Wales were excluded there were no marked difference in the 
prevalence of live births and fetal deaths. The difference of prevalence of anencephaly 
between the four states and three states was seen mainly in terminations of pregnancy before 
20 weeks gestation (Table 5.2, Table 5.3). Three states had, on average about 1.5/10,000 higher 
rate of early terminations than the rates in four states. Although there was a decrease in early 
termination rates in data from the four states, there was no marked decrease seen when the 
New South Wales data were excluded. The live birth rate has declined over the years, but fetal 
deaths have increased during those years indicating increased late terminations. In each year, 
about 80% of anencephaly-affected pregnancies in the three states were terminated before 20 
weeks of gestation.  
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Table 5.3: All anencephaly, including terminations of pregnancy, Vic, SA, and WA, 1998–2005 
  Live births  *Fetal deaths  **TOP <20 weeks 
  Number Rate(a) Number Rate(a) Number Rate(a) 
All 
Anencephaly Rate(a) 
1998 5 0.5 6 0.6 50 4.8 61 5.8 
1999 2 0.2 10 1.0 46 4.4 58 5.5 
2000 4 0.4 11 1.1 42 4.0 57 5.5 
2001 2 0.2 9 0.9 50 4.9 61 5.9 
2002 4 0.4 11 1.1 48 4.6 63 6.1 
2003 4 0.4 6 0.6 48 4.6 58 5.6 
2004 5 0.5 10 1.0 50 4.8 65 6.2 
2005 2 0.2 11 1.0 50 4.6 63 5.7 
Total 28 0.3 74 0.9 384 4.6 486 5.8 
(a) Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
**  TOP – Terminations of pregnancy before 20 weeks gestation. 
 
The prevalence of anencephaly largely fluctuated in all states during 1998 to 2005. The 
anencephaly rate in Victoria was lowest in 2000 and highest in 2004. There was no marked 
fluctuation in rates over the other years. South Australia had the lowest rates in 1999 and 2003, 
but the rate increased again after 2003. Western Australia had large fluctuations in rates of 
anencephaly-affected pregnancies between 4.3 and 8.3 per 10,000 pregnancies. New South 
Wales had generally lower rates and the rate gradually declined over the years, but this may 
be due to missing data. The average anencephaly rate in New South Wales was 2.6 per 10,000 
pregnancies while the other three states had averages between 5.5 and 6.2 per 10,000 
pregnancies (Figure 14). 
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    Figure 14: Estimated prevalence of anencephaly by state of women’s residence and year of birth               
or termination of pregnancy, NSW, Vic, SA and WA, 1998–2005 
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Prevalence of anencephaly in other countries/regions 
 
The rates given here include live births, stillbirths and terminations of pregnancy at all 
gestational ages for all countries and states/regions. The Australian rate was calculated using 
data from New South Wales, Victoria, South Australia and Western Australia. NTD rates for 
other countries are from the published data in the 2006 annual report of the International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). ICBDSR receives data 
from birth defect registers of many countries and regions. This comparison does not include 
data from countries where information on terminations of pregnancy before 20 weeks was not 
available. Instead, the data from some regional birth defect registers where terminations of 
pregnancy before 20 weeks information were presented are included in this section. The 
prevalence in Australia was similar to other developed countries such as Sweden and 
Norway. The prevalence reported by some regional birth defect registries showed a lower 
rate. Among countries who reported total anencephaly rates, Finland had the lowest rate.  
If the Australian rate is calculated using the data from Victoria, South Australia and Western 
Australia, the average rate would be 5.8 per 10,000 pregnancies, which is comparatively 
higher than some other developed countries. The high rate found from these states may 
illustrate a better ascertainment of data. 
 
 
Notes: Rates include live births, fetal deaths and terminations of pregnancy. 
Estimated Australian rate is based on data from New South Wales, Victoria, Western Australia and South Australia. 
Source: Australia - Australian Congenital Anomalies Monitoring System. 
Other countries - International Clearinghouse for Birth Defects Surveillance and Research, 2006 annual report. 
 
 Figure 15: International comparison of the rates of anencephaly, 2000–2004 
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Characteristics 
 
The characteristics in Table 5.4 are based on data from New South Wales, Victoria, South 
Australia and Western Australia, where details of terminations of pregnancy at less than 20 
weeks gestation are also provided. Therefore the women who have had early terminations are 
also included in this section, but some information was not complete for the early 
terminations. The number of women whose characteristics were analysed was 666.  
Almost all women who had a pregnancy affected with anencephaly had their age reported. 
Most women who were affected with anencephaly were in younger age groups. About 82% of 
affected women were younger than 35 years of age. A comparatively large number of teenage 
women had anencephaly-affected pregnancies. They had the highest rate among all age 
groups (6.0 per 10,000 pregnancies). Women aged 35 years or more had the lowest rate of 
pregnancies with anencephaly.  
Indigenous status was available for 90% of births, but only 35% of the terminations of 
pregnancy had Indigenous status recorded. Indigenous women had a nearly two-fold higher 
rate of births affected with anencephaly than the non-Indigenous women. This difference was 
statistically significant (PR=1.8, 95% CI 1.5–2.0). 
Plurality was reported for almost all affected pregnancies. Almost 6% affected pregnancies 
were multiple births. Women who had multiple births were more likely to have anencephaly 
affected births than women who had singleton births (PR=3.7, 95% CI 3.3–4.1).  
Data on sex was available only for births and some terminations of pregnancy. Many affected 
pregnancies were terminated early and sex was not reported. Available data show that there 
were more females with anencephaly. Of the reported births, about 49% were females and 
42% were males. The other 9% were reported as indeterminate sex. The available data show a 
slightly higher female predominance (Rate 1.3 versus 1.0 per 10,000 pregnancies). 
Almost three-quarters of pregnancies were diagnosed early and managed by termination 
before 20 weeks gestation. Only about 9% of pregnancies continued beyond 31 weeks 
gestation. However, 4.8% continued the pregnancy until term and 6.3% of them were 
Indigenous women. 
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Table 5.4: Characteristics of pregnancies affected with anencephaly, NSW, Vic,  
SA, and WA, 1998–2005 
Characteristics Number Per cent Rate 
Women's age group (years)(a)   
<20 38 5.7 6.0 
20–24 93 14.0 4.2 
25–29 215 32.3 4.8 
30–34 197 29.6 3.9 
≥35 109 16.4 3.8 
Not stated 14 2.1 .. 
Indigenous status(a)   
Indigenous 18 2.7 3.0 
Non-Indigenous 314 47.1 1.7 
Not stated 334 50.2 .. 
Plurality(a)    
Singleton 626 94.0 4.2 
Multiple 39 5.9 15.6 
Not stated 1 0.2 ..  
Sex(b)    
Male 109 16.4 1.0 
Female 126 18.9 1.3 
Indeterminate 23 3.5 .. 
Not stated 404 61.3 .. 
Gestational age(b)    
<20 484 72.7 .. 
20–31 119 17.9 35.9 
32–36 29 4.4 2.3 
≥37 32 4.8 0.2 
Not stated 2 0.3 .. 
(a) Rates are per 10,000 women who gave birth. 
(b)  Rates are per 10,000 live births and stillbirths. 
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Spina bifida 
Spina bifida includes meningocele, meningomyelocele, myelocele, myelomeningocele and 
rachischisis. Spina bifida is not counted when present with anencephaly.  
Spina bifida occurs when there is a failure of fusion of the posterior vertebral arch, resulting in 
various clinical manifestations depending on the location and type of defect. Spina bifida can 
be open or closed. Spina bifida occulta (closed) is the mildest form, and malformed vertebrae 
are covered by a layer of the skin. The open form includes meningomyelocele, in which the 
spinal cord and the meninges protrude through the opening in the spine, and meningocele, in 
which only the meninges protrude through the opening. Babies born with spina bifida may 
have various degrees of spinal cord and nerve damage. They may have varying degrees of 
paralysis of the lower limbs, learning disabilities, bowel and bladder complications and 
hydrocephalus, depending on the location of the malformation. With recent improvements in 
medical and surgical management, some of these children live into adulthood, but they 
continue to be at increased risk of morbidity and mortality throughout their life. The mortality 
rate for children with spina bifida is increased over the general population risk in the first year 
of life.  
The cost of providing medical care for a child with myelomeningocele has been estimated to 
be over US$70,000 (adjusted to 2001 US dollars) annually for the first 20 years of life, including 
the costs associated with an average of five surgeries per year in the first five years of life (20 
year lifetime cost is $1.4 million per case) (Detrait et al. 2005). 
The Australian Congenital Anomalies Monitoring System does not collect data on spina bifida 
occulta and sacrococcygeal teratoma without dysraphism. 
Prevalence 
There was a 25% decline in the prevalence of births with spina bifida from 1998 to 2003. The 
lowest rates were seen in 2002 and 2003 and rates increased again in 2004. The lowest live 
birth rate was in 2003 and the fetal death rate was lowest in 2002 (Table 6.1). 
Table 6.1: All spina bifida among births(a), Australia, 1998–2005 
 Year Live births Rate(b) *Fetal deaths Rate(b) All spina bifida Rate(b) 
1998 46 1.8 34 1.4 80 3.2 
1999 52 2.0 28 1.1 80 3.2 
2000 59 2.3 25 1.0 84 3.3 
2001 42 1.7 31 1.2 73 2.9 
2002 36 1.4 25 1.0 61 2.4 
2003 30 1.2 31 1.2 61 2.4 
2004 51 2.0 36 1.4 87 3.4 
2005 54 2.0 38 1.4 92 3.4 
1998–2005 370 1.8 248 1.2 618 3.0 
(a)  Includes all live births, stillbirths and pregnancy terminations of at least 20 weeks gestation or at least 400 g birthweight. 
(b)  Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
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About 60% of births were live births. More than 83% of them were alive at the end of the 
neonatal period. The proportion of babies alive on day 28 has not changed markedly during 
1998 to 2005. Neonatal death rates varied little throughout this period (Table 6.2).   
Table 6.2: Outcomes of the live births with spina bifida, Australia, 1998–2005 
 Year 
Live 
births Rate(a) 
Alive on 
day 28 Per cent Rate(b) 
Neonatal 
deaths Per cent Rate(b) 
1998 46 1.8 42 91.3 1.7 4 8.7 0.2 
1999 52 2.0 44 84.6 1.7 8 15.4 0.3 
2000 59 2.3 48 81.4 1.9 11 18.6 0.4 
2001 42 1.7 32 76.2 1.3 10 23.8 0.4 
2002 36 1.4 29 80.6 1.2 7 19.4 0.3 
2003 30 1.2 26 86.7 1.0 4 13.3 0.2 
2004 51 2.0 41 80.4 1.6 9 17.6 0.4 
2005 54 2.0 46 85.2 1.7 7 13.0 0.3 
1998–2005 370 1.8 308 83.2 1.5 60 16.2 0.3 
(a) Rates are per 10,000 live births and stillbirths. 
(b) Rates are per 10,000 live births. 
 
In New South Wales, Victoria, South Australia and Western Australia where terminations of 
pregnancy data were available, there was a 13.6% decrease in prevalence from 1998 to 2005. 
The rates of live births decreased until 2003 and increased again in 2004. The data from these 
four states had 32.2% live births and 42.3% of early terminations of pregnancy. However, 
67.8% of affected pregnancies resulted in fetal deaths or were managed by terminations of 
pregnancy.  
The rates of termination of pregnancy before 20 weeks fluctuated between 1998 and 2005. The 
rate was highest in 1999 and the lowest was in 2005. Nevertheless, the average termination of 
pregnancy before 20 weeks had a rate of 2.4 per 10,000 pregnancies (Table 6.3).  
 
Table 6.3: All spina bifida including terminations of pregnancy, NSW, Vic, SA, and WA, 1998–2005 
  Live births  Fetal deaths  TOP <20 weeks 
 Year Number Rate(a) Number Rate(a) Number Rate(a) 
All        
spina bifida Rate(a) 
1998 37 1.9 28 1.5 49 2.5 114 5.9 
1999 36 1.9 26 1.3 71 3.7 133 6.8 
2000 44 2.3 21 1.1 54 2.8 119 6.1 
2001 36 1.9 29 1.5 38 2.0 103 5.4 
2002 30 1.6 23 1.2 38 2.0 91 4.7 
2003 25 1.3 30 1.6 46 2.4 101 5.2 
2004 39 2.0 32 1.7 40 2.1 111 5.8 
2005 35 1.7 34 1.7 34 1.7 103 5.1 
1998–2005 282 1.8 223 1.4 370 2.4 875 5.6 
(a)  Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
**  TOP – Terminations of pregnancy before 20 weeks gestation. 
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Table 6.4: All spina bifida including terminations of pregnancy, Vic, SA, and WA, 1998–2005 
  Live births  *Fetal deaths  **TOP <20 weeks All 
 Year Number Rate(a) Number Rate(a) Number Rate(a) spina bifida Rate(a) 
1998 28 2.7 12 1.1 34 3.2 74 7.1 
1999 25 2.4 13 1.2 45 4.3 83 7.9 
2000 28 2.7 11 1.1 41 3.9 80 7.7 
2001 22 2.1 19 1.8 26 2.5 67 6.5 
2002 18 1.7 13 1.3 30 2.9 61 5.9 
2003 14 1.3 18 1.7 27 2.6 59 5.7 
2004 22 2.1 27 2.6 28 2.7 77 7.3 
2005 26 2.4 23 2.1 22 2.0 71 6.5 
1998–2005 183 2.2 136 1.6 253 3.0 572 6.8 
(a) Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
**  TOP – Terminations of pregnancy before 20 weeks gestation. 
 
After excluding data from New South Wales, the live birth and fetal death rates did not show 
a marked difference (Table 6.3, Table 6.4). Data from the three states (Victoria, South Australia 
and Western Australia) that have near complete data showed a slightly higher rate in early 
terminations. The overall prevalence of spina bifida in the three states was about 18% higher 
than the data from four states. Unlike anencephaly, more than 30% of pregnancies resulted in 
live births and most of those babies were still alive at the end of neonatal period. Between 1998 
and 2005, the proportions of pregnancy terminations before 20 weeks gestation in these three 
states varied by 30–50%. 
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        Figure 16: The prevalence of spina bifida by state of women’s residence and the year of birth or 
        terminations of pregnancy, NSW, Vic, SA and WA, 1998–2005 
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The prevalence of spina bifida was higher than the prevalence of anencephaly in each state. 
Western Australia and South Australia showed the highest prevalence. The highest rates were 
seen in Western Australia in 2004 and 2005. New South Wales showed a lower rate than 
Victoria, but these rates could be underestimations (Figure 16). The average spina bifida rate 
in New South Wales was 4.4 per 10,000 pregnancies while the other three states had averages 
between 6.2 and 7.7 per 10,000 pregnancies. 
Prevalence of spina bifida in other countries 
The rates in Figure 17 include live births, stillbirths and terminations of pregnancy at all 
gestations for all countries and states/regions. The Australian rate was calculated using data 
from New South Wales, Victoria, South Australia and Western Australia and given as an 
estimated rate for Australia. This prevalence could be an under-estimate because of some 
missing data, mainly from New South Wales.  
The prevalence of spina bifida in Australia was slightly higher than for national rates of other 
developed countries. Saxonyhalt of Germany showed the highest rate. The Alberta birth 
defects register showed the lowest rate.  
When the Australian rate is calculated using the data from Victoria, South Australia and 
Western Australia, the average rate would be 6.9 per 10,000 pregnancies, which is 
considerably higher than the rates in many other developed countries.  
 
 
Note: Rates include live births, stillbirths and terminations of pregnancy. 
Australian rate is based on data from New South Wales, Victoria, Western Australia and South Australia. 
Source:  Australia–Australian Congenital Anomalies Monitoring System. 
Other countries–International Clearinghouse for Birth Defects Surveillance and Research, 2006 annual report. 
 
Figure 17: International comparison of the rates of spina bifida, 2000–2004 
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Characteristics  
The rates presented in Table 6.5 are based on data from New South Wales, Victoria, South 
Australia and Western Australia where data include terminations of pregnancy. Some 
characteristics were not available for some terminations, but rates were computed for 
available data.  Characteristics are presented for 875 women. 
Women’s age was available for 96.7% of affected women. About 79% of affected women were 
less than 35 years of age. A considerably higher number of teenage women had a pregnancy 
affected with spina bifida and they had the highest rate among age groups. Women younger 
than 30 years of age had significantly higher rates of spina bifida affected pregnancies 
compared with women aged 30 years or more (PR= 1.3, 95% CI 1.2–1.5).  
About 28% of the women did not have Indigenous status reported. Available data showed 
that the Indigenous women were more likely to have spina bifida affected pregnancies than 
non-Indigenous women (PR=2.6, 95% CI 2.3–2.8).  
Sex was not available for most early terminations of pregnancy. Therefore, sex was not stated 
for about 30% of the data. The rate of females affected with spina bifida was slightly higher 
than the rate of males affected (3.6 per 10,000 versus 4.1 per 10,000). This difference was not 
statistically significant. 
Plurality was available for all pregnancies affected with spina bifida. Multiple pregnancies 
had nearly two times higher rate of spina bifida than the singleton pregnancies. Women who 
were pregnant with multiple fetuses were more likely to have spina bifida affected fetuses 
than women with singleton pregnancies (PR=1.9, 95% CI 1.7–2.1). 
About 42% of the pregnancies were detected early and terminated before 20 weeks of 
gestation. A quarter of pregnancies continued until full term. However 70% of the pregnancies 
did not continue beyond 31 weeks of gestation. 
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Table 6.5: Characteristics of pregnancies affected with spina bifida, NSW, Vic, SA, 
 and WA, 1998–2005 
Characteristics Number Per cent Rate 
Women's age group (years)(a)   
<20 45 5.1 7.0 
20–24 149 17.0 6.8 
25–29 271 31.0 6.1 
30–34 223 25.5 4.4 
35–39 132 15.1 5.5 
≥40 26 3.0 5.7 
Not stated 29 3.3 .. 
Indigenous status(a)   
Indigenous 38 4.3 10.3 
Non-Indigenous 594 67.9 4.0 
Not stated 243 27.8 .. 
Plurality(a)    
Singleton 848 96.9 5.7 
Multiple 27 3.1 10.8 
Sex(b)    
Male 286 32.7 3.6 
Female 307 35.1 4.1 
Indeterminate 7 0.8 .. 
Not stated 275 31.4 .. 
Gestational age(b)   
<20 370 42.4 .. 
20–31 239 27.4 97.9 
32–36 44 5.0 4.7 
≥37 219 25.1 1.5 
(a) Rates are per 10,000 women who gave birth. 
(b) Rates are per 10,000 live births and stillbirths. 
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Encephalocele 
 
Encephalocele could be only a protrusion of meninges through an opening in the skull or it 
could be protrusion of brain tissue with the meninges. It is often accompanied by craniofacial 
abnormalities or other brain malformations. This condition is less common than the spina 
bifida and anencephaly. The severity and prognosis depend on the type of brain tissue 
involved, the location of the sacs and the accompanying brain malformations. Occipital 
encephaloceles are more common in Western countries and anterior encephaloceles are 
common in Asian countries. Encephalocele is not counted when present with spina bifida or 
anencephaly in this report. 
 
Prevalence 
There was no change in the prevalence of births with encephalocele from 1998 to 2005. Neither 
the live birth rate nor the fetal death rate changed markedly during this period. About 61% of 
births were live births. More than 80% of them were alive on day 28. Neonatal death rates 
varied little throughout this period. 
Table 7.1: All encephalocele among births(a), Australia, 1998–2005 
 Year Live births Rate(b) *Fetal deaths Rate(b) All encephalocele Rate(b) 
1998 10 0.4 6 0.2 16 0.6 
1999 12 0.5 5 0.2 17 0.7 
2000 8 0.3 7 0.3 15 0.6 
2001 11 0.4 6 0.2 17 0.7 
2002 7 0.3 5 0.2 12 0.5 
2003 7 0.3 6 0.2 13 0.5 
2004 10 0.4 8 0.3 18 0.7 
2005 11 0.4 5 0.2 16 0.6 
1998–2005 76 0.4 48 0.2 124 0.6 
(a)  Includes all live births, stillbirths and pregnancy terminations with at least 20 weeks gestation or at least 400 g birthweight. 
(b)  Rates are per 10,000 live births and stillbirths. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
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Table 7.2: Outcomes of the live births of encephalocele, Australia, 1998–2005 
 Year 
Live 
births Rate(a) 
Alive on 
day 28 Per cent Rate(a) 
Neonatal 
deaths Per cent Rate(a) 
1998 10 0.4 7 70.0 0.3 3 30.0 0.1 
1999 12 0.5 9 75.0 0.4 3 25.0 0.1 
2000 8 0.3 8 100.0 0.3 0 0.0 0.0 
2001 11 0.4 9 81.8 0.4 n.p 18.2 0.1 
2002 7 0.3 7 100.0 0.3 0 0.0 0.0 
2003 7 0.3 6 85.7 0.2 n.p. 14.3 0.0 
2004 10 0.4 7 70.0 0.3 3 30.0 0.1 
2005 11 0.4 8 72.7 0.3 3 27.3 0.1 
1998–2005 76 0.4 61 80.3 0.3 15 19.7 0.1 
(a) Rates are per 10,000 live births and fetal deaths. 
 
The data from the four states providing information on termination of pregnancy showed that 
44.6% of affected pregnancies were terminated before 20 weeks of gestation. There was no 
significant difference in rates of live births and fetal deaths. About 30% of the pregnancies 
were live births. There was no decline in rates from 1998 to 2005. There was only a slight 
increase in rates, when New South Wales data were excluded.  
 
Table 7.3: All encephalocele including terminations of pregnancy, NSW, Vic, SA, and WA,          
1998–2005 
  Live births  Fetal deaths  TOP <20 weeks 
Year Number Rate(a) Number Rate(a) Number Rate(a) 
All   
spina 
bifida Rate(a) 
1998 5 0.3 6 0.3 8 0.4 19 1.0 
1999 9 0.5 5 0.3 11 0.6 25 1.3 
2000 5 0.3 5 0.3 19 1.0 29 1.5 
2001 7 0.4 6 0.3 8 0.4 21 1.1 
2002 4 0.2 5 0.3 9 0.5 18 0.9 
2003 7 0.4 6 0.3 7 0.4 20 1.0 
2004 7 0.4 7 0.4 8 0.4 22 1.1 
2005 8 0.4 5 0.2 8 0.4 21 1.0 
1998–2005 52 0.3 45 0.3 78 0.5 175 1.1 
(a) Rates are per 10,000 live births and stillbirth. 
 * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
**  TOP – Terminations of pregnancy before 20 weeks gestation. 
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Table 7.4: All encephalocele including terminations of pregnancy, Vic, SA, and WA, 1998–2005 
  Live births  *Fetal deaths  **TOP <20 weeks All          
Year  Number Rate(a) Number Rate(a) Number Rate(a) spina bifida Rate(a) 
1998 5 0.5 4 0.4 3 0.3 12 1.1 
1999 6 0.6 4 0.4 8 0.8 18 1.7 
2000 4 0.4 3 0.3 12 1.2 19 1.8 
2001 5 0.5 6 0.6 5 0.5 16 1.6 
2002 2 0.2 2 0.2 5 0.5 9 0.9 
2003 3 0.3 5 0.5 6 0.6 14 1.3 
2004 4 0.4 5 0.5 7 0.7 16 1.5 
2005 6 0.5 4 0.4 5 0.5 15 1.4 
1998–2005 35 0.4 33 0.4 51 0.6 119 1.4 
(a) Rates are per 10,000 live births and stillbirth. 
  * Fetal deaths include stillbirths and terminations of pregnancy with at least 20 weeks gestation. 
 ** TOP – Terminations of pregnancy before 20 weeks gestation. 
 
Pregnancies affected with encephalocele were rarer than the anencephaly and spina bifida in 
each state. All states had small numbers of affected pregnancies. Victoria had the largest 
numbers. South Australia did not have any affected pregnancies in 1998 and 2004 (Figure 18). 
The highest rates were seen in South Australia in 1999 and 2000. All states had variations in 
rates each year, but the highest rate was 2.2 per 10,000 pregnancies. The average encephalocele 
rate in New South Wales was 0.8 per 10,000 pregnancies while other three states had averages 
between 1.3 and 1.5 per 10,000 pregnancies. 
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    Figure 18: The prevalence of encephalocele by state of women’s residence and the year of   
birth or termination of pregnancy, NSW, Vic, SA and WA, 1998–2005 
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Prevalence of encephalocele in other 
countries/regions  
 
   
Notes: Rates include live births, fetal deaths and terminations of pregnancy. 
Australian rate is based on data from New South Wales, Victoria, Western Australia and South Australia. 
Source: Australia - Australian Congenital Anomalies Monitoring System. 
Other countries - International Clearinghouse for Birth Defects Surveillance and Research 2006 annual report 
 
Figure 19: International comparison of the rates of encephalocele, 2000–2004 
    
 
 
The Australian rates given in international comparison are based on data from New South 
Wales, Victoria, South Australia and Western Australia. This is a rare condition and the 
prevalence is low in all the other countries. However, some regions have slightly higher 
prevalence than others. The prevalence of encephalocele in Australia is similar to the other 
developed countries. 
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Characteristics 
The rates presented in Table 7.5 are based on 175 affected pregnancies from four states that 
include details of terminations of pregnancy. Some characteristics were not available for some 
terminations, but rates were computed for available data.  
Women of all age groups had similar rates of affected pregnancies, and teenage women had 
the lowest rate. About one-third of the women did not have Indigenous status reported. 
Available data show that Indigenous women are more likely to have encephalocele-affected 
pregnancies than non-Indigenous women. Sex was available for 66.3% of pregnancies. Male 
and female rates were similar for encephalocele. About 45% pregnancies were detected early 
and terminated before 20 weeks of gestation, but 22% of pregnancies continued until full term. 
Women who were pregnant with multiple fetuses were more likely to have encephalocele-
affected fetuses than women with singleton pregnancies. 
Table 7.5: Characteristics of pregnancies affected with encephalocele, NSW, VIC,  
SA, and WA,    1998–2005 
Characteristics Number Per cent Rate 
Women's age group(a)    
<20 5 2.9 0.8 
20–24 31 17.7 1.4 
25–29 43 24.6 1.0 
30–34 56 32.0 1.1 
35–39 27 15.4 1.1 
≥40 6 3.4 1.3 
Not stated 7 4.0 .. 
Indigenous status(a)    
Indigenous 6 3.4 1.6 
Non-Indigenous 105 60.0 0.7 
Not stated 64 36.6 .. 
Plurality(a)    
Singleton 163 93.1 1.1 
Multiple 11 6.3 4.4 
Not stated 1 0.6 .. 
Sex(b)    
Male 58 50.0 0.7 
Female 55 47.4 0.7 
Indeterminate 3 2.6 .. 
Gestational age(b)    
<20 78 44.6 .. 
20–31 47 26.9 19.2 
32–36 9 5.1 1.0 
≥37 39 22.3 0.3 
Not stated 2 1.1 .. 
(a) The rates are per 10,000 women who gave birth. 
(b) The rates are per 10,000 live births and stillbirths. 
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Conclusions and recommendations 
This report outlines the prevalence of all NTD including early terminations and the trends over 
the years from 1992 to 2005 in four jurisdictions including New South Wales, Victoria, South 
Australia and Western Australia and also presents estimated prevalence of NTD based on three 
states (data excluding New South Wales). The prevalence and trends of births with NTD are 
presented for all jurisdictions in Australia except Northern Territory from 1998 to 2005. As 
most NTD are obvious at birth and information is collected from multiple sources, the 
prevalence reported on births is expected to be accurate. This information will be useful in 
comparing the rates of NTD in the future, especially after mandatory fortification of flour with 
folic acid is introduced in September 2009. This information also will allow policy 
development and planning of services for the future. The information on live births, neonatal 
deaths and births that survived until the end of the neonatal period will be useful in planning 
services for future management and rehabilitation of the survivors. 
However, at least 50% of the pregnancies with NTD were terminated before 20 weeks 
gestation. Therefore collection of data on early terminations is critical in reporting the accurate 
prevalence of NTD. The report shows that the rates vary across all jurisdictions, so 
generalisation of findings are difficult.  
The total NTD rates for New South Wales, Victoria, South Australia and Western Australia 
include all terminations of pregnancy, but data from New South Wales was incomplete. 
Therefore estimated rates calculated using these four states could be under-estimates. 
Nevertheless, data for individual states can be used to compare rates for each jurisdiction in the 
future. As there were a large number of women who had pregnancies affected with NTD from 
these four states (including pregnancy terminations), findings on the characteristics of women 
and births was of value.  
The data from four states showed a decreasing trend in NTD since the early 1990s. This decline 
in NTD was approximately 33% between 1992 and 2005.  
Victoria, South Australia and Western Australia had near complete data and estimated 
prevalence based on data from these three states is expected to provide more reliable baseline 
estimates for total NTD prevalence prior to the introduction of mandatory fortification of bread 
flour with folic acid in Australia. The decline in NTD prevalence was 26% in these three states 
from 1992 to 2005. 
Folic acid fortification may cause beneficial effects on other congenital anomalies. This can be 
observed using data from the congenital anomalies monitoring systems’ database.  
The differences in data collected among the states demonstrate the need for a good quality 
national data set. A program of national data development is underway with the aim of 
developing a national minimum data set on congenital anomalies with the expectation of 
providing high quality national data on congenital anomalies. This initiative will assist the 
ACAMS in providing consistent national data on NTD that could be used in the future 
evaluation of the outcomes of mandatory folic acid fortification of bread on NTD. 
Ongoing data development and improvement of the quality of termination of pregnancy data in 
all jurisdictions are essential to support national reporting of congenital anomalies and to 
ensure the collection of high quality data.  
Since ACAMS is collecting only a limited number of data items, linking to other data sets that 
collect relevant data items will reduce the duplication of efforts.  
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Data development 
This report on neural tube defects in Australia is a part of the project funded by the Australian 
Health Ministers’ Advisory Council (AHMAC) through the Statistical Information 
Management Committee (SIMC) to work towards developing a National Minimum Data Set 
(NMDS) for congenital anomalies. NMDS is a minimum set of data elements agreed for 
mandatory collection and reporting at a national level. Definitions of all data elements that 
will be included in ACAMS National Minimum Data Set will be incorporated in the AIHW’s 
online metadata registry, METeOR. 
The development of data standards improves quality, makes data collection activities more 
efficient and reduces duplication of effort. It ensures that information to be collected is 
relevant and appropriate to its purpose and more comparable and consistent for reporting 
purposes.  
 
The development of an NMDS for congenital anomalies includes developing and agreeing on: 
• a definition for congenital anomalies 
• the scope of the NMDS, including the conditions to be included, the period of 
notification and the data elements to be included 
• the data element definitions 
• a classification for congenital anomalies 
• a time frame for implementation  
• integration with the Perinatal NMDS 
• producing congenital anomalies annual reports 
Part of the work of this project has been completed.  
 
A definition for congenital anomalies 
A definition for congenital anomalies has been drafted and circulated among the NCASC and 
STICCA members. Suggestions by the members were incorporated and it is pending 
recirculation for confirmation of the final definition. 
 
Developing ICD-10-AM classification for congenital anomalies 
Development of the classification system is a critical part of the developmental work of the 
ACAMS. Currently, none of the available coding systems have adequate specificity required 
to effectively classify congenital anomalies; different jurisdictions use diverse classifications 
that distort the consistency of the national data collection. NPSU aims to address this 
shortcoming and collect good quality data as far as possible. Precise coding ensures the 
accurate statistics which assist in preparing policy guidelines and planning for management of 
the illnesses and disabilities arising from congenital anomalies. 
Some jurisdictions use ICD-9-BPA to code congenital anomalies and others use ICD-10-AM. 
The jurisdictions using ICD-9-BPA have not moved to ICD-10-AM because it lacks specificity 
for some congenital anomalies. The National Centre for Classification in Health (NCCH) in 
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collaboration with the NPSU has already completed development of maps from ICD-9-BPA to 
ICD-10-AM, so that the data can be presented in a single classification in national reports. 
Mappings assist in extracting and analysing many years of data when there are differences in 
the coding.  
 
Development of ICD-10-AM classification 
Following is a description of the work that has been undertaken to develop the classification: 
A national committee was formed to develop the chromosomal abnormalities section of the 
ICD-10-AM. The members include Prof. Mac Gardner (Human Genetics Society of Australia), 
Prof David Tudehope (neonatologist, Mater Mother’s Hospital), Assoc Prof Liz Sullivan 
(NPSU), Assoc Prof Jane Halliday (Victorian Birth Defects Registry), Dr Felicity Collins 
(Clinical Geneticist), Dr Janet Vaughn (Feto Maternal Specialist), Dr Lynette Lee 
(Rehabilitation Physician), Dr David Lester-Smith (Paediatrcian), Ms Vera Dimitropoulos 
(NCCH), Ms Bronwyn Graham (NCCH), Ms Christine Erratt (NSW Birth Defects Register),  
Ms Sue Travis (NSW Birth Defects Register), Ms Merilyn Riley (Victorian Birth Defects 
Register), Ms Heather Scott (South Australian Birth Defects Register), Dr Samanthi 
Abeywardana (ACAMS).  
A national workshop was held at the NCCH in December 2007 to develop the ICD-10-AM 
classification for chromosomal abnormalities. The above committee representing many 
experts in relevant areas attended the workshop. Professor Mac Gardner prepared draft 
chromosomal abnormalities classification which was discussed at the workshop. A new 
classification with a more descriptive coding system that can be applied with ease to 
chromosomal abnormalities by all states and territories was proposed. It will replace the 
existing complex coding system. 
Some issues concerning the new chromosomal abnormalities classification were discussed at a 
teleconference in February 2008. Another meeting is to be held in August 2008 to finalise these 
changes. 
Since there were major changes to the existing system, approval from the World Health 
Organisation (WHO) to have necessary changes is a requirement. Therefore the new 
classification will not be adopted until the approval procedure is completed. 
Another workshop was held in May 2008 to discuss the cardio vascular system, respiratory 
system and digestive system. Assoc Prof Liz Sullivan (NPSU), Dr Kei Lui (neonatologist, 
Randwick Women’s Hospital), Ms Vera Dimitropoulos (NCCH), Ms Bronwyn Graham 
(NCCH), Ms Christine Erratt (NSW Birth Defects Register), Ms Sue Travis (NSW Birth Defects 
Register), Ms Sonya Palma (Victorian Birth Defects Register), Ms Heather Scott (South 
Australian Birth Defects Register), Ms Edwina Rudy (Western Australian Birth Defects 
Register), Ms Joanne Bunney and Ms Corrie Martin (Queensland Health Information Centre), 
Dr Samanthi Abeywardana (ACAMS) participated for this work shop. A comprehensive 
classification system for these systems was suggested during the workshop. 
There will be more workshops to complete this task before the end of 2008. 
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Clinical definitions 
The Australian Paediatric Surveillance Unit (APSU) has undertaken a project, in consultation 
with the NPSU, to develope nationally standardised clinical definitions for selected congenital 
anomalies that are adequate for the Australian context and will provide more accurate 
information about the prevalence of these conditions. APSU has completed definitions for the 
conditions included in the Australian congenital anomalies report, and is awaiting approval 
from the NCASC. 
A minimum dataset for congenital anomalies 
The work on development of the minimum dataset is ongoing. Congenital anomalies 
monitoring system’s staff had METeOR training to improve knowledge of data development 
principles and procedures. Some data elements have already been completed. The rest of the 
data elements will be completed within the next few months. 
Several committees will be involved in developing the dataset. The NPSU, NCASC, STICCA 
and when relevant, the National Perinatal Data Development Committee (NPDDC) will be 
consulted in the future. Following endorsement by the NCASC and the STICCA, submissions 
will be made to the Health Data Standards Committee (HDSC) and the SIMC.  
Proposed timeframe 
The proposed timeframe for the development of the NMDS for congenital anomalies is 
completion by March 2009, with implementation from 1 July 2009. The timeframe for the 
development of the ICD-10-AM classification for congenital anomalies is completion by early 
2009. 
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Appendix A: Denominator data 
Note: The source for all denominators is the National Perinatal Data Collection (Northern Territory excluded) 
 Table A: All births in Australia, 1998–2005 
  1998 1999 2000 2001 2002 2003 2004 2005 
All births 251,798 253,834 253,572 250,556 251,376 253,263 253,731 268,720 
Live births 249,952 252,075 251,793 248,828 249,699 251,478 251,834 266,783 
Women who gave birth 247,945 249,830 249,443 246,342 247,084 248,965 249,434 264,142 
 
 Table B: Number of all births by characteristics 1998–2005 
Sex Male 1,046,070 
 Female 990,089 
   
Gestational age (weeks) <32 33,168 
 32–36 125,568 
 ≥37 1,872,479 
   
Birthweight (grams) <1500 30,246 
 1500–2499 107,159 
 ≥2500 1,899,383 
 
 Table C: Number of births by plurality, Australia, 1998–2005 
 Plurality All births Live births 
Singleton 1,970,271 1,957,283 
Plural 32,913 32,296 
 
 Table D: Women who gave birth by age group, Australia, 1998–2005  
Live births + 
stillbirths <20 20–24 25–29 30–34 35–39 ≥40 
not 
stated Total 
1998 12,413 40,716 81,014 74,413 33,581 5,714 92 247,943 
1999 12,035 39,276 79,134 76,680 36,106 6,551 48 249,830 
2000 12,118 38,496 78,276 77,738 36,211 6,547 57 249,443 
2001 11,879 37,909 73,824 79,387 36,190 7,069 84 246,342 
2002 11,686 37,206 70,878 82,334 37,429 7,473 78 247,084 
2003 10,882 36,565 69,087 84,996 39,342 8,061 32 248,965 
2004 11,070 36,121 67,745 85,534 40,680 8,242 42 249,434 
2005 11,316 38,332 70,632 89,652 45,315 8,874 21 264,142 
1998–2005 93,399 304,621 590,590 650,734 304,854 58,531 454 2,003,183 
Live births 1998–2005 92,305 302,309 586,969 646,950 302,770 57,863 411 1,989,577 
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 Table E: Age group of women who gave birth by  
 gestational age at delivery, Australia, 1998–2005 
Women's age (years) <32 32–36 ≥37 
<20 2,267 6,238 84,454 
20–24 4,972 17,457 281,106 
25–29 7,742 31,155 550,109 
30–34 8,208 34,061 606,854 
≥35 5,949 22,482 334,072 
 
 Table F: Remoteness of the area of  
 residence, women who gave birth, 1998–2005 
Major cities 1,324,812 
Regional areas 564,914 
Remote areas 49,055 
 
 Table G: Outcomes of all births by Indigenous status of women  
 who gave birth, Australia, 1998–2005 
  Indigenous 
Non-
Indigenous Not stated 
Live births 69,840 1,902,349 533 
All births 70,684 1,914,946 581 
 
 Table H: Age group of women who gave birth by, Indigenous status, Australia, 
 1998–2005 
 Women's age (years) Indigenous Non-Indigenous Not known 
<20 15,719 78,748 31 
20–24 21,934 280,805 61 
25–29 17,487 568,657 123 
30–34 10,567 633,130 195 
35–39 4,222 296,567 126 
≥40 737 56,742 24 
Not stated 18 297 21 
 
 Table I: Indigenous status of women who gave birth by gestational age at delivery,  
 Australia, 1998–2005 
 Gestational age (weeks) Indigenous Non-Indigenous Not known 
<32 2,422 30,562 46 
32–36 7,396 117,971 41 
≥37 61,602 1,798,632 489 
Not stated 83 208 12 
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 Table J: Indigenous status of women who gave birth by plurality,  
 Australia, 1998–2005 
Plurality Indigenous Non-Indigenous Not known 
Singleton 69,877 1,883,249 574 
Multiple 807 1,916,603 7 
 
 
 Table K: Number of all births by individual states, NSW, Vic, Qld, SA and WA 1998–2005 
Year NSW Vic Qld SA WA 
1998 86,305 62,091 48,163 18,733 25,677 
1999 87,289 62,689 48,746 18,519 25,771 
2000 87,922 62,564 49,316 17,872 25,229 
2001 85,858 62,149 49,690 17,704 24,939 
2002 86,005 63,133 49,196 17,745 24,784 
2003 86,414 63,552 50,366 17,844 24,681 
2004 85,626 63,700 50,910 17,521 25,528 
2005 90,608 66,654 55,280 18,195 26,983 
1998–2005 696,027 506,532 401,667 144,133 203,592 
 
 
 Table L: Number of all births, NSW, 
 Vic, SA and WA, 1992–2005 
Year All births 
1992 200,749 
1993 197,748 
1994 197,888 
1995 196,152 
1996 194,045 
1997 194,283 
1998 192,806 
1999 194,268 
2000 193,587 
2001 190,650 
2002 191,667 
2003 192,491 
2004 192,375 
2005 202,440 
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  Table M: Number of all live births,  
  NSW, Vic, SA and WA, 1998–2005 
Year Live births 
1998 191,402 
1999 192,952 
2000 192,260 
2001 189,367 
2002 190,403 
2003 191,116 
2004 190,895 
2005 200,963 
 
 Table N: Women who gave births by age group, NSW, Vic, SA and WA, 1998–2005 
Women's age (years) 1998 1999 2000 2001 2002 2003 2004 2005 
<20 8,659 8,183 8,274 8,109 7,990 7,273 7,529 7,683 
20–24 29,663 28,269 27,844 27,367 26,913 26,238 25,820 27,100 
25–29 61,902 60,097 59,394 55,813 53,544 52,227 50,894 52,680 
30–34 58,367 60,351 60,973 61,926 64,260 66,004 66,438 69,140 
35–39 26,640 28,874 28,669 28,472 29,756 31,077 31,973 35,392 
≥40 4,540 5,363 5,244 5,655 5,906 6,398 6,490 6,975 
Not known 81 29 31 66 58 17 27 21 
 
 Table O: Number of all births, NSW, 
 Vic, SA and WA by sex, 1998–2005 
Male 795,480 
Female 754,203 
Indeterminate 166 
Not stated 435 
 
 Table P: Number of all births, NSW, Vic, SA  
  and WA by Plurality, 1998–2005 
Year Singleton Multiple 
1998 186,982 2,872 
1999 188,148 3,018 
2000 187,334 3,095 
2001 184,233 3,175 
2002 185,234 3,193 
2003 186,039 3,195 
2004 186,024 3,147 
2005 195,606 3,385 
1998–2005 1,499,600 25,080 
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 Table Q: Remoteness of the area of residence  
  of women, NSW, Vic, SA and WA, 1998–2005 
Major cities 1,113,578 
Regional areas 378,260 
Remote areas 32,175 
 
 Table R: Indigenous status by women’s characteristics,  
 NSW, Vic, SA and WA, 1998–2005 
  Indigenous Non-Indigenous 
All births 36,745 1,487,563 
Maternal age   
<20 8,110 56,232 
20–24 11,472 208,497 
25–29 9,037 438,816 
30–34 5,503 501,099 
35–39 2,219 237,040 
≥40 390 45,585 
Not known 14 294 
   
Gestational age   
20–31 1,161 20,319 
32–36 3,670 79,416 
≥37 31,908 1,387,677 
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Name      Position/Organisation 
Professor Elizabeth Elliott Chair/ Disciplines of Paediatrics and Child 
Health, University of Sydney and Director, 
Australian Paediatric Surveillance Unit  
Professor David Tudehope Deputy Chair/Director, Neonatal Intensive Care 
Unit, Mater Mother’s Hospital, Brisbane 
Professor Carol Bower Head, Division of Population Sciences, The 
University of Western Australia and Western 
Australian Birth Defects Register 
Associate Professor Elizabeth Sullivan AIHW, NPSU 
Associate Professor Jane Halliday Epidemiologist/Victorian Birth Defects Register, 
Head, Public Health Genetics, Murdoch 
Children's Research Institute 
Associate Professor Annabelle Chan Senior Medical Consultant, Pregnancy Outcome 
Unit, South Australian Department of Health 
Dr Hugh Martin Paediatric Surgeon, Royal Australasian College of 
Paediatric Surgeons 
Dr Lee Taylor Manager, Centre for Epidemiology and Research, 
NSW Department of Health  
Ms Sue Cornes Senior Director, Health Information Centre, 
Queensland Health 
State and Territory Implementation Committee for 
Congenital Anomalies 
Ms Merilyn Riley    Victorian Birth Defects Register 
Ms Sue Travis     Birth Defects Register, New South Wales 
Ms Edwina Rudy    Western Australian Birth Defects Register 
Ms Phillipa van Essen   South Australian Birth Defects Register 
Ms Maureen Bourne    Population Health Research Centre,  
Australian Capital Territory 
Mr Peter Mansfield Clinical Data Services, Department of Health and 
Human Services, Tasmania 
Ms Joanne Bunney Health Information Centre, Queensland 
Department of Health 
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